Illumina Inc (ILMN)

Daniel M. Skovronsky, MD, PhD, appointed to Illumina's Board of DirectorsJune 23, 2026 9:05 AM
PR Newswire (US) Eli Lilly and Company's Chief Scientific and Product Officer brings pharmaceutical R&D and scientific leadership perspective to Illumina's BoardSAN DIEGO, June 23, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced the appointment of Daniel M. Skovronsky, MD, PhD, to its Board of Directors, effective June 16, 2026. Dr. Skovronsky brings extensive experience in drug discovery, clinical development and translational medicine, which are areas directly relevant to Illumina's work advancing genomics and multiomics platforms. "Dan brings a rare combination of scientific expertise, innovation leadership, and healthcare impact," said Jacob Thaysen, chief executive officer of Illumina. "His experience building and advancing large research portfolios gives our Board a perspective that can help strengthen Illumina's ability to drive innovation across genomics, multiomics, and precision medicine."Dr. Skovronsky currently serves as Chief Scientific and Product Officer of Eli Lilly and Company and President of Lilly Research Laboratories, where he leads Lilly's global research and development organization and oversees commercial products across Lilly Cardiometabolic Health, Lilly Immunology, and Lilly Neuroscience.He joined Lilly in 2010, following the acquisition of Avid Radiopharmaceuticals, a company he founded in 2004 and led as Chief Executive Officer. Since joining Lilly, he has held roles of increasing responsibility across the organization.He previously served on the Board of Directors of Myriad Genetics, Inc.Dr. Skovronsky received a Bachelor of Science in molecular biophysics and biochemistry from Yale University and earned both his MD and PhD from the University of Pennsylvania. He completed residency training in pathology and fellowship training in neuropathology at the Hospital of the University of Pennsylvania.About IlluminaIllumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.ContactsInvestors:
Illumina Investor Relations
858-291-6421
IR@illumina.comMedia:
Christine Douglass
PR@illumina.com View original content to download multimedia:https://www.prnewswire.com/news-releases/daniel-m-skovronsky-md-phd-appointed-to-illuminas-board-of-directors-302807233.htmlSOURCE Illumina, Inc. Original: Daniel M. Skovronsky, MD, PhD, appointed to Illumina's Board of Directors

Illumina launches StrataMap Spatial Solution, a powerful end-to-end spatial whole transcriptome research solutionJune 8, 2026 9:15 AM
PR Newswire (US) StrataMap Spatial gives researchers access to spatial biology at true single cell resolution for discovery without boundariesWhole-transcriptome profiling across a large tissue capture area can generate 2x more unique genes per sample than probe-based technologiesSAN DIEGO, June 8, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced the launch of the StrataMap Spatial Solution, offering an unmatched breadth of coverage and resolution to redefine what researchers can detect with spatial transcriptomics. StrataMap Spatial, previously called the Illumina Spatial Solution, is an end-to-end sequencing-based research solution to uncover spatial insights. Spatial transcriptomics is already a critical tool in developmental biology, neuroscience, and oncology research. StrataMap Spatial expands researchers' ability to map tissue structure, reveal tissue function, track tumor progression, and identify novel drug targets for precision medicine. "Spatial biology offers a new perspective on how our genetic code manifests in our bodies," said Steve Barnard, PhD, chief technology officer of Illumina. "Our customers are already using StrataMap Spatial's unparalleled discovery power to map intricate tissues and study tumor development. This launch pairs our new spatial solution with our tailored bioinformatics pipeline, reinforcing Illumina's commitment to an insight ecosystem where data-at-scale becomes discovery without boundaries."Highest sensitivity spatial technology provides comprehensive transcriptomic insightsStrataMap Spatial gives customers a spatial solution with a large, flexible capture area, single-cell resolution, and unbiased whole-transcriptome profiling. Together, these features allow customers to holistically evaluate spatial relationships across cells, regions, and structures, for a more detailed view of tissue architecture and function. StrataMap Spatial's sequencing-based approach detects twice as many genes per sample than alternative, panel-based technologies. The solution goes beyond the coding transcriptome to detect noncoding genes and pseudogenes, uncovering the hidden signals that drive tissue function and disease. StrataMap Spatial is compatible with enrichment techniques, including those researchers use to identify relevant immune response markers like VDJ clonotypes.StrataMap Spatial meets the growing demand for scalable spatial biology studies from research and biopharma customers, through features such as:Capture area: The 7.5 cm2 capture area accommodates serial sections for researchers to create a multidimensional understanding of tissues. Users can also profile multiple fresh frozen tissue sections of varying sizes and shapes simultaneously. The solution is species-agnostic and accommodates a broad range of eukaryotic tissue samples and tissue RNA quality. Illumina is actively developing an FFPE-specific solution and targets initial customer enablement in 2027.Scale: StrataMap Spatial can process more than 2000 samples per year.Speed: Multiple slides can be run in parallel, with library preparation and sequencing following traditional NGS methods. Sequencing takes as few as 22 hours. Including imaging, sequencing, and analysis, customers can move from sample to insight in less than 5 days.Accessibility: Instead of investing in expensive, specialized systems, customers can integrate StrataMap Spatial into their existing histopathology workflows. StrataMap Spatial then runs on the NovaSeq and NextSeq platforms, giving existing customers an accessible entry point into spatial biology.Spatial-specific software provides powerful, scalable multiomic analysisStrataMap Spatial includes access to end-to-end bioinformatics that take customers from initial imaging through analysis. DRAGEN and Illumina Connected Multiomics efficiently process the large volume of resulting spatial data, maintaining the depth, resolution, and sensitivity produced by StrataMap Spatial. The DRAGEN StrataMap pipeline simplifies spatial exploration with machine-learning-driven cell segmentation, transcript assignment, and initial clustering. Illumina Connected Multiomics enables interactive, data-driven spatial analysis by combining tissue-level visualization with filtering, clustering refinement, and downstream biological interpretation. The platform enables the integration of transcriptomic data with genomic, epigenetic, and proteomic datasets. Layering these omics creates a more comprehensive understanding of the biological dynamics that shape human health.Early work with StrataMap Spatial examines tumor microenvironments, charts development of complex tissuesIn a pilot, researchers from Beth Israel Deaconess Medical Center (BIDMC) used StrataMap Spatial to map historically challenging lymphatic tissues and produced the first whole transcriptome spatial datasets for human lymphatic collector vessels. Dr. Ioannis Vlachos, PhD, director of the Spatial Technologies Unit within BIDMC, and his team reconstructed 3D models of tissue organization at cellular resolution from serial sections imaged on StrataMap Spatial."Illumina's StrataMap Spatial exhibited high sensitivity, which enabled us to shed light on these exceptionally challenging samples, said Dr. Vlachos, "StrataMap's large capture area permitted us to place multiple serial sections to establish whole transcriptome, single cell resolution, 3D maps of these exceptionally precious tissues and unlock novel biology."Researchers at Cancer Research UK Cambridge Institute and University of Cambridge trialed StrataMap Spatial on an initial set of primary central nervous system tumors. The team was led by Richard Mair, PhD, a neurosurgeon at Addenbrooke's Hospital and a University of Cambridge scientist, in collaboration with the Spatial Profiling Annotation Centre of Excellence (SPACE) led by Dario Bressan, PhD. The team evaluated glioma and glioblastoma tissues to characterize their complex tumor microenvironment, with the ultimate goal of guiding more precise surgical interventions and personalized treatment choices."Until now, we were unable to study large tissue sections in CNS and other cancer types at a whole-transcriptome, single-cell level," said Ania Piskorz, PhD, the Head of Genomics at the Cancer Research UK Cambridge Institute and University of Cambridge. "Unlocking the ability to profile these large tissue sections will provide deeper insights into the tumour microenvironment. It will help us build more informative tumour maps, identify mechanisms of treatment resistance, and improve our ability to predict patient therapeutic responses."Ania Piskorz is presenting the group's early work on June 10 at the European Association for Cancer Research meeting. You can also visit Illumina's booth at EACR from June 8-11 to learn how StrataMap Spatial can amplify your cancer research.StrataMap Spatial is available to order this month.You can read more about StrataMap Spatial here.Use of forward-looking statementsThis release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) challenges inherent in developing and launching new products and services, including modifying and scaling manufacturing operations, and reliance on third-party suppliers for critical components; (ii) our ability to manufacture robust instrumentation and consumables and develop reliable software solutions; and (iii) the acceptance and adoption by customers of our newly launched or updated products, which may or may not meet our and their expectations, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current quarter.About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.ContactsInvestors:
Illumina Investor Relations
858-291-6421
IR@illumina.comMedia:
Christine Douglass
PR@illumina.com View original content to download multimedia:https://www.prnewswire.com/news-releases/illumina-launches-stratamap-spatial-solution-a-powerful-end-to-end-spatial-whole-transcriptome-research-solution-302793726.htmlSOURCE Illumina, Inc. Original: Illumina launches StrataMap Spatial Solution, a powerful end-to-end spatial whole transcriptome research solution

Illumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology researchMay 28, 2026 12:30 PM
PR Newswire (US) Automating library prep reduces hands-on time for customers using Pillar Biosciences oncoReveal® targeted oncology research panelsSAN DIEGO, May 28, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) and SPT Labtech today introduced the fireflyGO automation platform, a new benchtop liquid handling and library preparation solution that brings automation, speed, and simplicity to targeted oncology research. Integrated with the MiSeq™ i100 Series, fireflyGO helps laboratories streamline workflows, expand application flexibility, and unlock genomic insights with greater efficiency. By making next-generation sequencing (NGS) more accessible, scalable, and easier to adopt, Illumina continues to accelerate the shift toward genomics in cancer testing and as a standard of care in oncology. "Illumina is delivering end-to-end workflow solutions that help customers across the healthcare and research ecosystem make genomic testing more efficient and accessible," said Sandy Ottensmann, vice president and general manager of Global Clinical Solutions. "The fireflyGO platform paired with Illumina MiSeq i100 sequencers and Pillar Biosciences targeted panel assays advances research and serves as a catalyst for broadening genomic testing in cancer, driving shorter turnaround times leading to fast results."Simplified automation for targeted oncology workflowsThe fireflyGO platform automates library preparation and liquid handling as part of a streamlined workflow for sequencing and analysis on the MiSeq i100 Series. The workflow reduces manual touchpoints, providing higher reproducibility and reliability while reducing laboratory staffing needs. This solution also enables automation capabilities for a growing menu of NGS panels developed by Pillar Biosciences, supporting Illumina's targeted oncology research portfolio."Simplifying oncology workflows improves research and access to testing with the goal of delivering treatment faster. Our collaboration with Illumina reflects a shared focus on enabling efficient and accessible genomics workflows," said Rob Walton, chief executive officer at SPT Labtech. "By combining SPT Labtech's expertise in automation with Illumina's global strength in sequencing, we are positioned to help labs adopt genomics workflows."Expanding Illumina's oncology research portfolioIllumina is also expanding its Pillar Biosciences oncoReveal® targeted research portfolio with panels and workflows focused on solid tumor and hematologic malignancies and lymphoid conditions to enable rapid and simplified results:The oncoReveal® Nexus 21 Gene Panel offers rapid solid tumor and hematological malignancy sequencing for multiple cancer types including NSCLC, endometrial, AML, B-Cell Lymphoma and MPN.The oncoReveal® Lymphoid Panel is an 84 gene DNA panel spanning high-value B-cell, T-cell, and lymphoblastic markers including full coverage of BTK to help genomically characterize lymphoid malignancies including CLL/SLL, WM/LPL, FL, MCL, DLBCL/LBCL, HCL, and multiple T-cell entities.These oncoReveal panels are currently available to customers worldwide.Expanding access to NGS in oncology clinical researchThe fireflyGO automation liquid handler, together with Illumina sequencing platforms and partner-developed content like Pillar oncoReveal panels, reinforces Illumina's mission to improve human health by unlocking the power of the genome.To see and learn more about the fireflyGO platform with the MiSeq i100 and Pillar oncoReveal panels, visit the Illumina booth, #33106, at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 29 through June 2.Use of forward-looking statementsThis release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) challenges inherent in developing, manufacturing, and launching new products and services;  (ii) our and our partners' ability to deploy new products, services, and applications, and to expand the markets for genomics-related products and services; and (iii) the challenges associated with multiparty collaborations, including our reliance on the performance of such partners,  together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current quarter.About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.ContactsInvestors:
Illumina Investor Relations
858-291-6421
IR@illumina.comMedia:
Christine Douglass
PR@illumina.com View original content to download multimedia:https://www.prnewswire.com/news-releases/illumina-and-spt-labtech-unveil-fireflygo-enabling-faster-simpler-targeted-oncology-research-302784759.htmlSOURCE Illumina, Inc. Original: Illumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology research

Illumina introduces the first distributed whole-genome sequencing solution for highly sensitive MRD researchMay 28, 2026 9:15 AM
PR Newswire (US) An advanced research workflow for fast, flexible detection of molecular residual disease during and following treatmentSolution is the first in a new WGS oncology portfolio, building on Illumina's history of leadership as foundation for MRD marketSAN DIEGO, May 28, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced a new complete solution for molecular residual disease (MRD) research based on whole-genome sequencing (WGS). As a distributed kit, it will enable more labs to adopt MRD detection for clinical research. Now in early access for select clinical research partners, the MRD solution is the first whole-genome kit with flexibility to enable solid tumor MRD and blood cancer genomic profiling. It is the first in a new portfolio of WGS oncology research offerings, with additional solutions in development leveraging the latest advancements of the NovaSeq X™. "In precision healthcare, early and accurate detection of molecular residual disease is critical to monitoring patients during and after cancer treatment," said Todd Christian, senior vice president of Services, Arrays and Genomic Access at Illumina. "Illumina's MRD solution for clinical research leverages the advanced sensitivity of whole-genome sequencing, coupled with unparalleled analysis, to enable our customers to more easily deliver the most precise information to advance MRD research. We aim to make WGS in oncology more accessible and scalable to support the integration of precision solutions into the standard of care."The MRD solution supports "fingerprinting" through solid tumor samples, and MRD detection using blood samples, all compatible on NovaSeq Systems. The end-to-end research workflow can be completed in as fast as 5 days and is optimized for analytical sensitivity as low as 10 ppm, particularly important for early-stage and low-shedding tumors, including breast, ovarian, and renal.Illumina's first-of-its-kind DRAGEN™ MRD analysis connects each fingerprint to serial circulating tumor DNA (ctDNA), offering customers flexible workflow combinations to meet their specific needs. Leveraging DRAGEN's unparalleled speed and accuracy, the new MRD solution has been optimized across thousands of samples to develop and demonstrate a ctDNA detection algorithm with 99.5% analytical specificity to distinguish true tumor signals from background noise.Early adopters see strong performance with Illumina's WGS oncology solution Several academic institutes evaluated the workflow. Mayo Clinic evaluated the solutioni on a small sample cohort and found high concordance among previously characterized paired samples. The results were also highly correlated with clinical and imaging results over time. The team is planning to expand the cohort for additional research with Mayo Clinic and other academic partners."We are looking forward to participating in early access and evidence generation for a tumor-informed, non-bespoke whole-genome sequencing approach to MRD," said Gang Zheng, MD, PhD and professor of Laboratory Medicine and Pathology at Mayo Clinic. "We have seen early pilot results across several solid tumor clinical samples that demonstrated the potential utility of highly sensitive solid tumor MRD detection, and we continue to pilot technologies that help us efficiently progress in our ability to analyze and translate complex genomic arrays." Illumina and Bristol Myers Squibb will jointly present a poster at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting on Sunday, May 31, from 9:00 a.m. to 12:00 p.m. (abstract ID 8591, poster board #381, Lung Cancer: Non–Small Cell Metastatic track). More information can be found at this link. Roadmap to achieve ultra-sensitivity tailored for broader adoptionBuilt on recently announced NovaSeq X advancements, including 35B output and Q70 quality scores, a complementary research workflow that will deliver ultra-sensitive MRD detection in the single-digit ppm range leveraging duplex reads is currently in development."Illumina continues to push the NovaSeq X's capabilities to help our customers break barriers and unlock more discoveries," said Steve Barnard, PhD, chief technology officer of Illumina. "The new portfolio will bring advanced MRD research directly into labs with unmatched speed and sensitivity. The NovaSeq X is built for the long term, and Illumina will continue to deliver technologies that empower our customers to accelerate oncology breakthroughs."Illumina technology also fuels centralized MRD providers leading the market today. The NovaSeq X offers foundational capabilities to support the quality, reliability, and scale needed as MRD adoption continues to grow. Illumina's new oncology portfolio builds upon the unique, integrated insight ecosystem of workflows, data and community across genomic, multiomic, and clinical research applications—anchored on the NovaSeq X.Illumina's MRD research solution is available today for early access to select partners and will launch for global customers next year. Learn more here.  Use of forward-looking statements
This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) iiour ability to successfully implement NovaSeq X updates on a cost-effective and timely basis, (ii) challenges inherent in developing and launching new products and services, including modifying and scaling manufacturing operations, and reliance on third-party suppliers for critical components; (iii) our ability to manufacture robust instrumentation and consumables and develop reliable software solutions; and (iv) the acceptance and adoption by customers of our newly launched or updated products, which may or may not meet our expectations and theirs, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation and do not intend to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current quarter.About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.Contacts
Investors:
Illumina Investor Relations
858-291-6421
IR@illumina.comMedia:
Christine Douglass
PR@illumina.com___________________i As an early user, Mayo Clinic independently executed and evaluated the assay in their lab.ii As of the Q4 financial disclosures, the NovaSeq X active install base was 890 at the end of FY2025.  View original content to download multimedia:https://www.prnewswire.com/news-releases/illumina-introduces-the-first-distributed-whole-genome-sequencing-solution-for-highly-sensitive-mrd-research-302784511.htmlSOURCE Illumina, Inc. Original: Illumina introduces the first distributed whole-genome sequencing solution for highly sensitive MRD research

David P. King elected to Illumina's Board of DirectorsMay 21, 2026 4:15 PM
PR Newswire (US) Former Labcorp Chairman and CEO brings deep healthcare, diagnostics, and clinical expertise to Illumina's BoardSAN DIEGO, May 21, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today confirmed the election of David P. King to its Board of Directors, effective immediately following the company's annual meeting of shareholders. Mr. King's election marks an important addition to Illumina's Board as the company accelerates its clinical strategy to integrate genomics more broadly into the standard of care."We are delighted to welcome David to the Illumina Board," said Jacob Thaysen, chief executive officer of Illumina. "David brings deep regulatory knowledge, broad industry credibility, and the respect earned over decades at the forefront of healthcare and life sciences. Under his leadership at Labcorp, the company tripled in size through organic growth and strategic acquisitions. His perspective across diagnostics, healthcare delivery, and board governance will strengthen our ability to deliver long-term impact for patients, customers, and shareholders."Mr. King is the former Executive Chairman and Chief Executive Officer of Labcorp. Under his leadership, Labcorp entered the Fortune 500, and was recognized by Fortune as one of the World's Most Admired Companies.Mr. King joins the Board following the retirement of Frances Arnold, PhD, Robert S. Epstein, MD, and Gary S. Guthart, PhD, each of whom concluded distinguished tenures on the Board at the company's annual meeting.About David P. KingDavid P. King was elected to Illumina's Board of Directors in 2026. Mr. King has extensive experience in the healthcare and life sciences sectors in executive and non-executive roles, including leading complex businesses at scale, driving operational excellence and commercial initiatives, and executing transformational change through M&A and organic growth. Mr. King served as Chair and Chief Executive Officer as well as Executive Chairman of Laboratory Corporation of America Holdings (Labcorp) from 2007 to 2019. He provides strategic advisory services across the healthcare ecosystem through KingMan LLC. Mr. King also serves as Chair of Privia Health Group, Inc., as a director of Smith & Nephew, and has served in board leadership roles across a range of healthcare companies, including as Chair of ZimVie (2022–2025) and as Non-Executive Chair of PathGroup, LGC Limited, and AmSurg. Earlier in his career, Mr. King was a partner at Hogan & Hartson LLP (now Hogan Lovells) and served as an Assistant U.S. Attorney for the District of Maryland. Mr. King received a B.A. from Princeton University and a J.D. from the University of Pennsylvania Law School.About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit?illumina.com?and connect with us on?X,?Facebook,?LinkedIn,?Instagram,?TikTok, and?YouTube.ContactsInvestors:  
Illumina Investor Relations 
858-291-6421 
IR@illumina.comMedia:? 
Christine Douglass 
PR@illumina.com View original content:https://www.prnewswire.com/news-releases/david-p-king-elected-to-illuminas-board-of-directors-302779474.htmlSOURCE Illumina, Inc. Original: David P. King elected to Illumina's Board of Directors

Illumina releases 2025 Corporate Responsibility Report, expanding access to genomics and accelerating global impactMay 19, 2026 4:30 PM
PR Newswire (US) SAN DIEGO, May 19, 2026 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today published its annual Corporate Responsibility (CR) Report. The report highlights the company's continued progress in expanding equitable access to genomics while delivering measurable impact for patients, communities, and health systems worldwide. It reinforces Illumina's mission-driven culture, sustainability goals, and commitment to genomics for good."More than 20 million people are diagnosed with cancer each year. Rare disease patients face years-long diagnostic odysseys to find answers. Health systems are under growing pressure to deliver better outcomes with fewer resources. Genomics can help meet these challenges, but only if it is integrated into real-world settings at scale," said Jacob Thaysen, CEO of Illumina. "The exceptional pace of sequencing on Illumina platforms—over 10 human genomes per minute in 2025—is a strong signal that we are meeting the moment, bringing us closer to a future where personalized medicine improves outcomes for all."Expanding access to genomics at scale across the globeIllumina is enabling cost-effective, scalable technologies while championing global policies and initiatives to improve access to genomic medicine. In 2025, Illumina partnered with governments, health systems, and research institutions for population-scale genomics, sovereign data stewardship, and national precision health initiatives that reflect local needs and priorities. The Illumina Corporate Foundation supported efforts around the world to bring next-generation sequencing to patients without access. Illumina contributed to international policy efforts to prioritize rare disease in public health and participated in rare disease hackathons where our new technologies and employee expertise interrogated genomic challenges.Continuing leadership in sustainability, community engagementIllumina recognizes that human health and environmental health are fundamentally linked, driving the company to reduce its environmental footprint across business practices while supporting customers' ability to sequence more sustainably. Since 2019, Illumina has reduced product packaging by 87%, surpassing its 2030 target. Over the same period, the company has reduced Scope 1 and 2 greenhouse gas emissions by 74% and achieved 100% renewable electricity for the fourth consecutive year through renewable energy procurement, onsite solar generation, and renewable energy credits (RECs). These efforts earned Illumina recognition as one of TIME's World's Most Sustainable Companies for the second year in a row.Reflecting the company's commitment to nurturing our people and community, Illumina maintained a zero net pay gap for the seventh consecutive year and surpassed its goal of 100,000 volunteer hours by 2030. Employees have contributed more than 116,000 volunteer hours since 2019, with 50% of employees participating in giving and volunteering opportunities in 2025. Employees routinely bring their passion for education to the classroom, investing in the next generation of scientists. Illumina has reached 2.6 million STEM learners since 2019, including 500,000 in 2025 alone.As part of the company's dedication to innovation, Illumina continues to expand access to genomic technologies across research, clinical, and population health settings. In 2025, the company launched the Illumina 5-base solution and Illumina Protein Prep, updated the DRAGEN software pipeline, and expanded our oncology portfolio. Illumina also debuted new capabilities such as PromoterAI and strengthened global collaborations with the Alliance for Genomic Discovery, Broad Clinical Labs, and more.Illumina is pleased to share all of this information and more in its 2025 Corporate Responsibility report, available here.Forward-Looking Statements
This communication contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, among others, statements regarding Illumina's expectations, plans, and the potential impact of its technologies and initiatives, and are based on Illumina's current expectations, assumptions, and beliefs. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.  Forward-looking statements may be identified by words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "likely," "may," "plan," "potential," "project," "seek," "will," and similar expressions. Factors that could cause actual results to differ materially include, among others: challenges inherent in developing and commercializing new technologies; the rate of adoption of genomic solutions by customers and health systems; regulatory developments and reimbursement considerations; and other factors described in Illumina's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Illumina undertakes no obligation to update any forward-looking statements except as required by law.About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube. Illumina Contacts:  Investors:
Illumina Investor Relations  
858-291-6421  
IR@illumina.com Media: 
Christine Douglass  
PR@illumina.com  View original content:https://www.prnewswire.com/news-releases/illumina-releases-2025-corporate-responsibility-report-expanding-access-to-genomics-and-accelerating-global-impact-302775660.htmlSOURCE Illumina, Inc. Original: Illumina releases 2025 Corporate Responsibility Report, expanding access to genomics and accelerating global impact

DRAGEN v4.5 supports Illumina's new TruPath Genome and 5-base assays, drives insights across germline, oncology, and multiomic workflowsApril 16, 2026 9:15 AM
PR Newswire (US)

Illumina launches DRAGEN v4.5, unlocking deep biological signals in complex regions and challenging sample types for rare disease, oncology research New pangenome representation, default personalization, and machine learning features boost analytical capabilities across applications  SAN DIEGO, April 16, 2026 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today announced the launch of DRAGEN™ version 4.5 software (v4.5), one of the most substantial expansions of the software's capabilities to date. As genomic researchers contend with complex regions of the genome, degraded samples, and multiomic data types, DRAGEN v4.5 delivers new ways to reduce noise, improve accuracy, and extract biological signals, giving researchers greater discovery power to fuel findings in rare disease and oncology.This release enhances DRAGEN's strong germline foundation with expanded pangenome representation and personalization, further improving variant calling accuracy and performance in challenging genomic regions. v4.5 provides analytical support for Illumina TruPath™ Genome, resolving challenging-to-map regions of the genome."These advances expand the scope of biological questions researchers can address across germline, oncology, and multiomic applications—while maintaining the speed, scale, and operational consistency expected from DRAGEN," said Rami Mehio, senior vice president and general manager of BioInsight at Illumina. "BioInsight is all about making bioinformatics accessible, reliable, and scalable, whether you are a researcher seeking insights into rare disease or a pharma partner pursuing drug discovery from datasets."DRAGEN v4.5 key updatesSignificantly expands multiomic analysis, with structural variant calling and improved small variant accuracy for Illumina's 5-base solution, enabling more integrated genetic and epigenetic insightIntroduces machine-learning-driven somatic analysis and expands oncology insights with new capabilities like oncovirus detectionStrengthens the scalable multiomic pipelines that support ambitious projects, like the recently announced Billion Cell AtlasDavid Spencer, a researcher at Washington University School of Medicine in St. Louis, applied v4.5 to his trial of Illumina's 5-base assay on acute myeloid leukemia, or AML, samples. Genetic mutations detected at diagnosis are important predictors of clinical outcomes in AML. Persistent mutations in remission are also predictive of relapse. Spencer is exploring whether epigenetic changes can be used as biomarkers to further improve predictions of relapse. His team found that 5-base provided highly accurate methylation information and detected abnormal epigenetic patterns in samples with clonal disease in remission, highlighting the potential of integrated genetic and epigenetic analysis to improve disease characterization and monitoring."Illumina 5-base and DRAGEN v4.5 combine variant detection and methylation with added structural-variant calling capabilities, expanding the set of genomic changes that can be explored as potential biomarkers in AML samples," said Spencer.Personalization, machine learning are among new features of DRAGEN v4.5Advances in v4.5 enhance secondary analysis in genomic and multiomic workflows.  New algorithms support Illumina TruPath™ Genome: v4.5 introduces analytical support for TruPath, leveraging algorithmic advances to resolve 15 highly homologous, medically-relevant genes for rare disease research.Personalization improves germline variant calling: Personalization by default further reduces germline small variant errors, delivering approximately a 20% reduction in false positives and false negatives compared to v4.4.Pangenome better reflects global genomic diversity and reduces ancestry-related bias: The addition of Middle Eastern reference genomes expands the DRAGEN pangenome to better represent global population diversity, improving mapping and variant calling across underrepresented ancestries. In parallel, targeted improvements to the SMN1 variant caller enable detection of silent carriers, addressing a known source of underdiagnosis in certain populations.Machine learning expands Illumina's 5-base solution: The release introduces structural variant calling for both germline and somatic applications of 5-base, alongside improved germline small variant accuracy and personalization enabled by data specificity and machine learning. Illumina Connected Annotation further supports these analyses by highlighting genomic regions of interest informed by methylation data, simplifying interpretation of complex multiomic datasets.Oncology features bring bioinformatics power to complex cancer questions Formalin fixed paraffin embedded (FFPE) samples present substantial technical noise that can make it difficult to identify relevant variants. v4.5's machine-learning-driven somatic small variant calling reduces FFPE-associated false positives by over 90% for single nucleotide variants and over 87% for indels—improving sensitivity without increasing runtime or computational burden. Opt-in machine learning separates true variants and background artifacts, improving sensitivity at low tumor purity. This enables more reliable detection of biologically relevant variants in challenging samples.Additionally, v4.5 debuts robust oncovirus detection. Certain viruses, such as human papillomavirus (HPV), can drive cancer development by disrupting normal cellular control mechanisms, sometimes through integration of viral DNA into the host genome. In internal tests, v4.5 detected 100% of expected oncoviruses and identified 18 additional oncoviruses, showcasing the software's sensitivity for high-risk strains of HPV and Epstein-Barr Virus. Researchers can use this information to develop new tests and targets for oncovirus-driven cancers.The software is available via on-premises servers and in the cloud. Register today for our April 30 technical webinar to see DRAGEN v4.5 in action and read the technical blog to learn more.Use of forward-looking statementsThis release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) challenges inherent in developing, manufacturing, and launching new products and services; (ii) customer uptake of, and satisfaction with, new products and services; and (iii) legislative, regulatory and economic developments, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current quarter.About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.ContactsInvestors:
Illumina Investor Relations
858-291-6421
IR@illumina.comMedia:
Christine Douglass
PR@illumina.com



View original content:https://www.prnewswire.com/news-releases/dragen-v4-5-supports-illuminas-new-trupath-genome-and-5-base-assays-drives-insights-across-germline-oncology-and-multiomic-workflows-302744328.htmlSOURCE Illumina, Inc.

Original: DRAGEN v4.5 supports Illumina's new TruPath Genome and 5-base assays, drives insights across germline, oncology, and multiomic workflows

Illumina and the Center for Data-Driven Discovery in Biomedicine bring genomic data and scalable software to the fight against pediatric cancer and rare diseaseApril 14, 2026 9:15 AM
PR Newswire (US)

Dataset will drive crucial insights to accelerate scientific discovery and ultimately improve pediatric patient care. SAN DIEGO, April 14, 2026 /PRNewswire/ -- Illumina (NASDAQ: ILMN) and the Center for Data-Driven Discovery in Biomedicine (D3b) today announced a data partnership to advance research in pediatric cancer and rare disease. Through cloud-based data platforms, the global research community can unify and analyze pediatric data within a single, scalable discovery environment, enabling real-time, cross-cohort analysis and accelerating translation to clinical care.Through this initiative, D3b is analyzing 100,000 whole genomes from pediatric patients using Illumina software solutions. This is one of the largest unified genomic datasets ever assembled. D3b and Illumina are enabling discovery at a scale not previously possible, making the resulting insights available through the Gabriella Miller Kids First Data Resource Center (Kids First DRC). This data empowers researchers and clinicians to uncover the biological origins of rare disease and cancer and translate findings for pediatric precision medicine.Congenital conditions and cancers are a leading cause of death in children yet critical data are often siloed across institutions. Shared genomic data ecosystems enable researchers and clinicians to compare cases across large cohorts, validate diagnoses, and inform treatment strategies based on prior patient experiences."Genomic datasets like these give researchers powerful insight for precision medicine," said James Han, vice president of Bioinformatics at Illumina. "Through advances in data, software, and AI, we are moving toward a future where genomic insights drive faster research breakthroughs.""We're excited to apply leading-edge software technology against some of the toughest challenges in pediatric cancer and congenital conditions," said Allison Heath, director of Data Technology and Innovation at D3b. "Our goal is to empower researchers to uncover new biological signals and to bring genomic insights into routine clinical decision-making, creating a new standard of care."The dataset will include whole genomes from patients with rare congenital conditions and cancers, collected through federally-funded programs, including the Kids First DRC and the Children's Brain Tumor Network (CBTN). The samples are being analyzed with DRAGEN v4.4 and Illumina Connected Analytics (ICA) to create a comprehensive dataset with the accuracy, speed, and scale necessary for meaningful, cross-sample insights.The initial cohort demonstrated the power of DRAGEN algorithms to correct known errors and reveal structural variants that previous bioinformatics tools were unable to identify. Additionally, Illumina is joining D3b in supporting the Pediatric Care eXpansion (PCX) program of the Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services (HHS). The effort aims to shorten the care journey for patients from months to weeks by expanding data-sharing capabilities across a national data exchange spanning more than 200 pediatric institutions in the United States, providing clinicians with timely and seamless access to previously unattainable health data and insights, enabling them to learn from real-world patient trajectories across multiple institutions and provide more personalized care for each patient.About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.About the Center for Data-Driven Discovery in Biomedicine
The Center for Data-Driven Discovery in Biomedicine (D3b) is a global leader in advancing pediatric research through the integration of data science, technology innovation, and collaborative discovery. Established in 2016 to accelerate cures for children with cancer and other complex diseases, D3b builds and operates pioneering cloud-based platforms that connect researchers, clinicians, patients, and advocates worldwide.Home to transformative initiatives such as the Children's Brain Tumor Network (CBTN), the Gabriella Miller Kids First Data Resource Center (Kids First DRC), and the RADIANT AI project, D3b develops scalable data ecosystems, harmonized biospecimen resources, and next-generation analytics to fuel breakthroughs in diagnosis, treatment, and clinical care. By uniting multi-institutional expertise with open science principles, D3b empowers discoveries that no single institution could achieve on its own.Guided by the strategy to harness big data and global collaboration, D3b continues to shape the future of precision medicine, ensuring that every child, regardless of disease, geography, or background, benefits from the most advanced research and therapies.ContactsIlluminaInvestors:
Illumina Investor Relations
858-291-6421
IR@illumina.comMedia:
Christine Douglass
PR@illumina.com 



View original content:https://www.prnewswire.com/news-releases/illumina-and-the-center-for-data-driven-discovery-in-biomedicine-bring-genomic-data-and-scalable-software-to-the-fight-against-pediatric-cancer-and-rare-disease-302741288.htmlSOURCE Illumina, Inc.

Original: Illumina and the Center for Data-Driven Discovery in Biomedicine bring genomic data and scalable software to the fight against pediatric cancer and rare disease

Illumina to Announce First Quarter 2026 Financial Results on Thursday, April 30, 2026April 9, 2026 4:30 PM
PR Newswire (US)

SAN DIEGO, April 9, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the first quarter 2026 following the close of market on Thursday, April 30, 2026.On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results. Conference Call DetailsThe conference call will begin at 1:30 pm Pacific Time (4:30 pm Eastern Time) on Thursday, April 30, 2026. Interested parties may access the live webcast via the Investor Info section of Illumina's website or directly through the following link - https://illumina-earnings-call-q1-2026.open-exchange.net/. To ensure timely connection, please join at least ten minutes before the scheduled start of the call.A replay of the conference call will be posted on Illumina's website after the event and will be available for at least 30 days following.About IlluminaIllumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and connect with us on X (Twitter), Facebook, LinkedIn, Instagram, TikTok, and YouTube.Investors:
Conor McNamara
+1.858.291.6421
ir@illumina.comMedia:
Christine Douglass
pr@illumina.com



View original content:https://www.prnewswire.com/news-releases/illumina-to-announce-first-quarter-2026-financial-results-on-thursday-april-30-2026-302737292.htmlSOURCE Illumina, Inc.

Original: Illumina to Announce First Quarter 2026 Financial Results on Thursday, April 30, 2026

Illumina Announces Changes to Board of DirectorsApril 2, 2026 9:07 AM
PR Newswire (US)

David P. King nominated to support next phase of growth and innovation;
Frances Arnold, Robert S. Epstein, and Gary S. Guthart to retire from the BoardSAN DIEGO, April 2, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced changes to its Board of Directors. Frances Arnold, PhD, Robert S. Epstein, MD, and Gary S. Guthart, PhD, will retire from the Board in connection with the company's upcoming annual meeting of shareholders, and the Board has nominated David P. King to be elected as a member of the Board. 







"On behalf of the entire Board and management team, I want to thank Frances, Robert, and Gary for their exceptional service to Illumina," said Scott Gottlieb, MD, Chair of the Board. "Their sound judgment and steady commitment helped steer the company through a period of transformation. Additionally, we're pleased to nominate David King to the Board. Dave brings operating experience, public company board leadership, and regulatory insight forged across the healthcare and life sciences landscape. He has led complex organizations and advised companies at the intersection of innovation and patient care, translating technological advances into scalable, real-world applications that improve healthcare. With strong Board support, Illumina continues to lead the industry in advancing the integration of genomics into the practice of medicine."About David P. King
David P. King has extensive experience in healthcare and life sciences, serving in executive and non-executive roles. Mr. King is the former Executive Chairman and CEO of Laboratory Corporation of America Holdings, and currently serves as a director and chair of both Privia Health and AmSurg Corporation, and as a director of Smith & Nephew. His board experience includes recent positions at several healthcare companies including ZimVie (2022-2025), VaxCare (2021-2025), and Health Channels. Before joining LabCorp in 2001, Mr. King was a partner at Hogan & Hartson LLP (now Hogan Lovells) where he was a key leader in the firm's healthcare fraud and abuse practice, representing healthcare companies in investigations and litigation.About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit?illumina.com?and connect with us on?X,?Facebook,?LinkedIn,?Instagram,?TikTok, and?YouTube.ContactsInvestors:
Illumina Investor Relations 
858-291-6421 
IR@illumina.comMedia:
Christine Douglass 
PR@illumina.com



View original content to download multimedia:https://www.prnewswire.com/news-releases/illumina-announces-changes-to-board-of-directors-302732352.htmlSOURCE Illumina, Inc.

Original: Illumina Announces Changes to Board of Directors

Illumina and Labcorp expand collaboration to broaden access to precision oncology testingMarch 18, 2026 9:15 AM
PR Newswire (US)

SAN DIEGO, March 18, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) and Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced an expanded collaboration to advance precision oncology through innovative applications of next-generation sequencing (NGS) solutions across the healthcare ecosystem. Projects are expected to include promoting equitable access to cancer biomarker testing by bringing it closer to patients through new distributed test offerings; generating evidence to facilitate payer coverage; and developing new tests to address areas of unmet need."By deepening our collaboration, we'll continue to leverage the strengths of our respective teams to innovate and improve access to critical biomarker testing for patients with cancer," said Traci Pawlowski, vice president of Clinical Product Development at Illumina. "Our longstanding collaboration is rooted in a shared vision to advance precision oncology through groundbreaking research and leading-edge technologies."New test development is expected to span advanced oncology research and in vitro diagnostic (IVD) tests for comprehensive genomic profiling (CGP) and whole-genome sequencing (WGS). These solutions will aim to address areas of unmet needs in precision oncology and help bridge existing testing gaps.As part of the collaboration, the companies will explore co-commercializing Labcorp's FDA-authorized liquid biopsy assay PGDx elio® plasma focus™ Dx alongside Illumina's FDA-approved TruSight™ Oncology Comprehensive for solid tumor profiling. Together, these distributed IVD test kits are intended to expand access to both tissue and liquid biopsy testing for hospitals and community health systems—bringing advanced biomarker testing closer to patients and helping to provide more specific diagnoses and identify eligibility for targeted treatments and clinical trials. This distributed offering also aims to provide pharmaceutical companies with differentiated opportunities for companion diagnostic (CDx) development, supporting both tissue and liquid biopsy needs for targeted therapy approvals."This collaboration reflects Labcorp and Illumina's shared commitment to improving cancer care through innovation and access," said Shakti Ramkissoon, MD, PhD, MBA, vice president and medical lead for oncology at Labcorp. "Building on our longstanding medical and scientific collaborations and our ongoing efforts to generate clinical evidence and expand access to advanced genomics, we are combining our expertise to deliver transformative testing solutions that support more timely, equitable cancer care."Illumina and Labcorp will also continue joint efforts to demonstrate the clinical utility of CGP and promote its adoption. In a collaborative study published in Frontiers of Oncology, researchers evaluated more than 7,600 non-small cell lung cancer (NSCLC) tumor samples. The study applied Illumina CGP to demonstrate its coverage and utility in detecting known and novel genomic features of NSCLC. Results showed that CGP detected variants with a current targeted therapy or clinical trial in more than 72% of patient tumors.This is one of eight joint publications in oncology between Illumina and Labcorp since 2022, along with 18 posters and presentations made at industry conferences."Expanding access to advanced genomic testing is essential to delivering personalized cancer care," said Pawlowski. "Together with Labcorp, we are accelerating innovation to bring critical insights closer to patients and enable better outcomes across diverse care settings."Use of forward-looking statements
This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) challenges inherent in researching, developing and launching new technologies; (ii) our and our partners' ability to deploy new products, services, and applications, and to expand the markets for genomics-related products and services; and (iii) the challenges associated with multiparty collaborations, including our reliance on the performance of such partners,  together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current quarter.About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.Contacts Investors:
Illumina Investor Relations
858-291-6421
IR@illumina.comMedia:
Christine Douglass
PR@illumina.com



View original content:https://www.prnewswire.com/news-releases/illumina-and-labcorp-expand-collaboration-to-broaden-access-to-precision-oncology-testing-302716715.htmlSOURCE Illumina, Inc.

Original: Illumina and Labcorp expand collaboration to broaden access to precision oncology testing

Illumina advances preventive genomics through strategic consortium with Veritas GeneticsMarch 16, 2026 9:15 AM
PR Newswire (US)

New collaboration aims to bring population-scale whole-genome sequencing into everyday healthcare, enabling earlier risk detection and data-driven preventionSAN DIEGO, March 16, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced a strategic collaboration with Veritas Genetics Powered By Fuze Health to form a consortium that aims to bring preventive genomics into everyday healthcare through health insurance plans in the United States and under other global markets, setting a new standard for proactive health management. By combining clinical-grade sequencing, advanced informatics, and member-ready reporting, the collaboration supports an integrated data ecosystem to advance research, drug discovery, and clinical trial optimization.Built around a shared vision for data-driven precision medicine, the collaboration aims to integrate whole-genome sequencing into proactive healthcare. It will empower individuals to proactively leverage whole-genome data to support earlier identification of disease risk, more personalized prevention strategies, and improved long-term health outcomes."Genomics is increasingly moving upstream in healthcare, from diagnosing disease to helping prevent it," said Rami Mehio, general manager, BioInsight at Illumina. "By combining Illumina's sequencing and informatics backbone with Veritas' patient-ready reporting, this collaboration represents an important step forward in making preventive genomics actionable, accessible, and integrated into everyday healthcare.""The myGenome whole-genome sequencing comprehensive genetic risk service has been developed to integrate into a health insurer's environment and enable members to benefit from preventive genomics at a personalized level," said Javier de Echevarría, CEO, Veritas Genetics and Chief Genomics Officer, Fuze Health.The consortium is designed to provide:An opt-in preventive genomics program that delivers actionable genomic insights and connects those insights to appropriate interventions.Integrated care pathways for actionable findings, including confirmatory testing, specialist referral where appropriate, guideline-aligned screening, and prevention programs.A streamlined member experience supported by simple sample collection, clear education and consent, results delivery, and access to genetic counseling.A consented, integrated clinical-genomics dataset to enable industry partnerships across precision medicine.The collaboration is structured around distinct but complementary roles, where Veritas has elected to build and validate workflows based on Illumina sequencing and informatics technologies; including WGS, DRAGEN analysis methods and pipelines, and AI enabled insights. Veritas will provide the experience layer, including interpretation capabilities with myGenome reporting, clinical interpretation, and access to genetic counseling services. The collaboration also seeks to create opportunities to leverage the full breadth of Fuze Health capabilities to support bringing genomic insights into care pathways.Together, the consortium aims to enable earlier identification of elevated risk across areas such as hereditary cancer, cardiometabolic disease, and medication response, helping shift care from reactive treatment to proactive prevention. This initiative builds on Illumina's broader strategy to expand the clinical utility of genomics and support scalable, evidence-based adoption across the healthcare ecosystem.Use of forward-looking statementsThis release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) our and our partners' ability to deploy new products, services, and applications, and to expand the markets for genomics-related products and services; and (ii) the challenges associated with multiparty collaborations, including our reliance on the performance of such partners,  together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current quarter.About Illumina Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube. About Veritas Genetics Powered by Fuze HealthVeritas Genetics is a leader in clinical genomics, offering advanced human-genome sequencing and interpretation services to enable accurate diagnosis, personalized prevention, and improved healthcare decision-making. Veritas is part of Fuze Health, a technology-powered home health screening, genomics and pharmacy services provider committed to transforming patient experiences and enabling healthcare partners – including care providers, health plans, employers and life sciences companies – to excel in an outcomes-focused system.Contacts? Investors: 
Illumina Investor Relations 
858-291-6421 
IR@illumina.com Media: 
Christine Douglass 
PR@illumina.com 



View original content:https://www.prnewswire.com/news-releases/illumina-advances-preventive-genomics-through-strategic-consortium-with-veritas-genetics-302714332.htmlSOURCE Illumina, Inc.

Original: Illumina advances preventive genomics through strategic consortium with Veritas Genetics

Illumina whole-genome sequencing technology to accelerate rare disease testing in FloridaFebruary 27, 2026 9:15 AM
PR Newswire (US)

Increased adoption of clinical whole-genome sequencing is advancing diagnostics for rare diseases, which affect 15 million American childrenSAN DIEGO, Feb. 27, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that Illumina Laboratory Services, Illumina's CLIA-certified laboratory, is providing clinical sequencing and interpretation services to the new Diagnostic Lab at Florida Institute for Pediatric Rare Diseases (IPRD) at Florida State University (FSU) College of Medicine, further driving innovation in diagnostics and treatments for rare diseases.







"An estimated 30 million people across the country are living with a rare disease today and clinical whole-genome testing provides a transformative opportunity to end the diagnostic odyssey for patients," said Eric Green, MD, PhD, chief medical officer of Illumina. "Our colleagues at IPRD will now be equipped to break diagnostic barriers, and we are proud to help them accelerate making life-saving discoveries."Diagnosing rare genetic diseases is challenging—advanced genomic sequencing and interpretation are crucial for uncovering novel mutations that can be hidden in deep parts of the genome. Furthermore, results must be reliable and actionable for clinicians who are often presented with diseases they have never encountered previously. Illumina's goal is to equip more labs with the solutions and tools they need to diagnose rare diseases more consistently and help reduce the time it takes to transition from diagnosis to clinical management."I've been running Illumina sequencers for over 10 years, but it's a new ball game when you're talking about clinical samples," said Cynthia Vied, PhD, scientific director, IPRD Diagnostic Lab at FSU College of Medicine. "We have learned how to do things much differently in the clinical lab compared to my work in the research facility, and I think it has helped both sides.""Now, all the work we do means we can impact a patient—a child—and a family going through a challenging health situation," continued Vied. "We can help them understand and hopefully help the physicians provide a treatment based on the diagnoses that we're going to provide from the lab. That, to me, is extraordinary."   Building on a long-standing relationship between Illumina and FSU College of Medicine, the IPRD Diagnostic Lab utilized services from the Illumina Customer Success and Implementation team for workflow enablement. Illumina Laboratory Services enabled the IPRD Diagnostic Lab to rapidly initiate their clinical diagnostic testing through clinical genome sequencing and interpretation services.With a mission to improve human health by unlocking the power of the genome, Illumina is proud to support customers like IPRD who are dedicated to finding answers for patients with rare genetic disease. In recognition of Rare Disease Day, Dr. Green is speaking at FSU today, February 27. The event will be livestreamed and available for playback here. Read more about how Illumina is supporting the rare disease community here.About IlluminaIllumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.    Contacts Investors: 
Illumina Investor Relations
858-291-6421
IR@illumina.comMedia: 
Christine Douglass
PR@illumina.com



View original content to download multimedia:https://www.prnewswire.com/news-releases/illumina-whole-genome-sequencing-technology-to-accelerate-rare-disease-testing-in-florida-302699193.htmlSOURCE Illumina, Inc.

Original: Illumina whole-genome sequencing technology to accelerate rare disease testing in Florida

Illumina partners go beyond the genome, driving cancer breakthroughs using spatial transcriptomics, epigenomics, and proteomicsFebruary 25, 2026 9:15 AM
PR Newswire (US)

At AGBT, researchers reveal new findings from studies leveraging Illumina's multiomics solutionsSAN DIEGO, Feb. 25, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced new customer breakthroughs in oncology powered by Illumina's spatial transcriptomics, 5-base sequencing, and proteomics technologies. The ability to combine more than one omic insight reveals unprecedented biological depth and knowledge, all of which is streamlined by Illumina Connected Multiomics for multimodal data analysis. The combined portfolio delivers new insights for precision diagnostics, targeted therapeutics development, and understanding of tumor microenvironments."Unlocking the human genome has changed the face of cancer care and opened up demand for the next wave of biological insights," said Jacob Thaysen, chief executive officer at Illumina. "Researchers are rapidly adopting multiomics and informatics technologies that expand our understanding of biology at scale. Illumina's streamlined multiomics workflows are enabling customers to achieve game-changing breakthroughs in oncology, pharmacogenomics, and more."Illumina Spatial Technology decodes complex tissues with easeThe human lymphatic system is notoriously difficult to map due to its size and variability among individuals. Spatial technology holds promise to probe biomolecular signatures that can improve the diagnosis and prognosis of cancer and even explain how it metastasizes in the body.Dr. Ioannis Vlachos, PhD, director of the Spatial Technologies Unit within Beth Israel Deaconess Medical Center (BIDMC), leveraged Illumina Spatial Technology and visualization software to investigate human lymph nodes and lymphatic channels."Our research as an NIH HuBMAP Tissue Mapping Center aims to shed light on the complex function of lymphatic vessels, which are exceptionally challenging samples due to their low adhesion, surrounding adipose tissue, and small size. Illumina Spatial Technology generated high-quality data from samples ranging from very small to quite sizable, producing the first ever whole transcriptome spatial datasets for human lymphatic collector vessels," said Vlachos. "The large capture area and serial sections helped us resolve single-cell-thick layers and reconstruct three-dimensional representations of tissue organization with whole transcriptome capture at 1um resolution. Our institution and the broader research community can use these datasets to answer many possible research questions."In another study conducted by Illumina researchers, Illumina Spatial Technology outperformed other competing technologies for improved sensitivity, higher resolution, and higher throughput at a lower cost.The study mapped breast cancer progression across a range of precancerous to high-grade ductal carcinomas. Whole-transcriptome profiling revealed unexpected nuances of tumor microenvironments, including identification of a novel set of cancer-associated fibroblasts. Researchers found more than 2000 unique transcripts in each cell, showing an unprecedented level of sensitivity."Each tumor is unique and its gene expression is never uniform," said Cande Rogert, vice president and global head of advanced sciences at Illumina. "By interrogating a large surface area of tissue at high resolution, we were able to analyze the tumor genetics within their real context and identify new cell subtypes. The resulting multiomic insights provide additional information and have the potential to drive more precise therapeutic development."Illumina 5-base solution delivers epigenetic context for cancer diagnosticsA team of researchers from Broad Clinical Labs, working with hospital research partners in Boston and Europe, recently explored the application of Illumina's 5-base solution to support clinical research for pediatric kidney cancer. This type of cancer typically requires invasive surgical procedures to diagnose, monitor, and treat that are not always feasible.The researchers are seeking genomic alternative approaches. Existing translational research ctDNA assays can miss disease signals in very rare tumors such as Wilms and rhabdoid. Illumina's 5-base solution enabled simultaneous genomic and methylation profiling to add additional epigenomics signals that identify cases missed by conventional approaches. Illumina 5-base whole genomes from renal cancer patients were tested in methylation-based classifiers and were able to predict the presence of rhabdoid tumors missed by genomics-only methods. Future work will expand 5-base profiling to additional FFPE and cfDNA samples, with the goal of training advanced machine learning models. These efforts may ultimately provide clinicians with more accurate diagnostic insights and improve outcomes for patients. "Combining these molecular signals in a single, scalable process can help us develop non-invasive diagnostics for cancers," said Carrie Cibulskis, director of cancer genomics at Broad Clinical Labs. "We're working toward a minimally invasive methylation-aware assay for cancer diagnosis and treatment selection."Integrated multiomics improves understanding of advanced ovarian cancer Nearly 80% of ovarian cancers are diagnosed at advanced stages, where survival drops to about 30%. When caught early, survival exceeds 90%. For women presenting with an adnexal mass, accurately distinguishing between benign and malignant disease is critical to guiding appropriate referral and surgical care, yet current diagnostic tools lack sufficient accuracy to reliably support these decisions.Bodour Salhia, PhD, a professor of cancer biology at the University of Southern California's Keck School of Medicine applied Illumina's 5-base solution, Illumina Protein Prep, and Illumina Spatial Technology to adnexal masses. The method enabled them to more easily differentiate between cancerous and benign tumor types using cell-free DNA and explore more sensitive ways to gain deeper biological context for ovarian cancer. Results included the first reported spatial analyses of adnexal masses and revealed localized tumor biology not previously reported."These findings create a multiomic framework for ovarian cancer research and lay the groundwork for an effective liquid biopsy in particularly challenging ovarian cancers with the potential to transform diagnostic practices and outcomes," said Salhia. "Layering the omics gave us a winning combination, providing more context for earlier cancer identification."Illumina's 5-base solution allowed for sensitive, integrated genetic and methylation analysis of tumor samples without compromising specificity. The methylation signals separated malignant and benign samples better than traditional approaches, which can often fail to separate cell types.Illumina Protein Prep allowed the researchers to identify novel gene sets, proteins, and pathways in ovarian cancer, creating new lines of inquiry in cancer biology research, biomarker and drug development. Layering Protein Prep and 5-base data through a custom pipeline in Illumina Connected Multiomics quickly resolved a false positive case.The layered approach helped researchers establish parameters for targeted exploration of gene expression in spatial data. Using Illumina Spatial Technology, transcriptomic data helped to resolve signals driving false positive results.Illumina Connected Multiomics accelerates sample-to-answer pipelineMultimodal analytics from Illumina Connected Multiomics provides deeper insights and overcomes the fragmented, siloed views produced by isolated assays, empowering researchers with a new understanding of cancer mechanisms, tumor heterogeneity, and potential therapeutic targets.Illumina unveiled new product updates and customer data during the Gold Sponsor Workshop at the Advances in Genome Biology and Technology (AGBT) annual meeting in Orlando. Learn more about Illumina's activity at AGBT here. Use of forward-looking statementsThis release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) challenges inherent in researching, developing and launching new technologies, including modifying and scaling manufacturing operations, and reliance on third-party suppliers for critical components; (ii) our ability to manufacture robust instrumentation and consumables and develop reliable software solutions; (iii) our ability to deploy new products, services, and applications, and to expand the markets for genomics-related products and services, and (iv) the acceptance and adoption by customers of our newly launched or updated products, which may or may not meet our and their expectations, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current quarter.About IlluminaIllumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.Contacts Investors:
Illumina Investor Relations
858-291-6421
IR@illumina.comMedia:
Christine Douglass
PR@illumina.com





View original content to download multimedia:https://www.prnewswire.com/news-releases/illumina-partners-go-beyond-the-genome-driving-cancer-breakthroughs-using-spatial-transcriptomics-epigenomics-and-proteomics-302696646.htmlSOURCE Illumina, Inc.

Original: Illumina partners go beyond the genome, driving cancer breakthroughs using spatial transcriptomics, epigenomics, and proteomics

Illumina launches TruPath Genome, setting a new standard in genomic insightFebruary 24, 2026 12:15 PM
PR Newswire (US)

TruPath™ Genome offers more complete genome, with the simplest sample to sequencer workflowData presented at AGBT demonstrates TruPath Genome's accuracy in detecting rare genetic diseaseBroad Clinical Labs is among first to adopt product, which was previously known as "constellation mapped read technology"SAN DIEGO, Feb. 24, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced the launch of TruPath™ Genome, setting a new standard for high-quality, comprehensive whole genome insights for genetic disease. TruPath Genome has been found to deliver unparalleled accuracy and resolution—even across so-called "dark regions" of the genome—providing researchers with a more complete picture of genomic alterations implicated in genetic disease.



With an incredibly simple workflow, TruPath Genome eliminates traditional library prep. In about 10 minutes of hands-on time, TruPath Genome generates 16 whole genomes per day, nearly double the throughput of competing long-read methods, and with fewer errors.TruPath Genome leverages novel on-flow cell library preparation with patterned flow cell technology and advanced informatics to seamlessly add long-distance insights for comprehensive variant detection. DRAGEN™ algorithms tuned to incorporate proximity information from TruPath flow cells improve read alignment and variant calling, extending Illumina high-quality reads to difficult-to-map regions, variant phasing, structural variants, short tandem repeats (STR), and clinically relevant paralogous genes. TruPath Genome fully phases up to 98% of genes."With TruPath Genome, we are pushing the boundaries of genomics and setting a new standard for genetic and rare disease research," said Steve Barnard, PhD, chief technology officer of Illumina. "In rare disease, you're often looking for a variant needle in a genomic haystack—and comprehensiveness, accuracy, and confidence matter. This technology unlocks rapid answers to shed light on the genomic drivers of genetic disease with an ease that was never thought possible."TruPath Genome delivers a highly cost-effective whole genome workflow solution at a $395 USD list price. This includes all consumables and analysis, at an industry standard depth of at least 30x coverage with single-use flow cell, which is critical in clinical research.Data presented at AGBT illustrates a short-read path to long-distance insight
Data presented today at AGBT and in previous publications illustrates how TruPath Genome is already shedding light on some of the most challenging genetic diseases, including spinal muscular atrophy, kidney disease, and complex adrenal disorders.Researchers at University Medical Center Utrecht presented data evaluating TruPath Genome in challenging rare disease samples, with a particular focus on long-range phasing performance required to support non-invasive prenatal diagnostic (NIPD) assays, as well as resolution of difficult genomic regions and complex structural variants."TruPath Genome enabled us to consolidate multiple analyses into a single, easy-to-implement whole-genome assay," said Marcel Nelen, PhD, head of the Genome Diagnostic Laboratory at UMC Utrecht. "Despite the simplicity of the workflow, we achieved megabase-scale phasing, full resolution of clinically relevant genes, and improved interpretation of difficult regions—even a particularly challenging case in the notoriously complex SMN1/SMN2 region—as well as complex structural variants. This represents an important step toward a single assay capable of addressing many rare disease research questions without additional orthogonal testing."At the recent Festival of Genomics & Biodata in London, researchers from the University of Exeter shared data on their pilot of TruPath Genome, which found that the technology resolved highly complex genomic regions, including a gene known to be associated with inherited adrenal disorders. While current short-read WGS requires parental samples to identify compound heterozygotes, TruPath Genome offers a single-sample path to these insights, improving coverage for samples processed without parental data."TruPath Genome opens up a future where every patient affected by a rare genetic condition can receive rapid comprehensive whole-genome testing to end diagnostic odysseys and identify possible precision treatments," said Emma Baple, PhD, professor of Genomic Medicine at the University of Exeter and medical lead for the NHS England Rapid Genome Sequencing Service for Critically Unwell Children. "In Exeter, we have been privileged to evaluate the TruPath technology and seen the potential to change the lives of affected children and their families. We are eager to see how this innovation evolves, as these types of solutions will transform how rare conditions are diagnosed."Broad Clinical Labs is among the first to adopt TruPath Genome, which will make this important technology available to their collaborators in rare disease research."TruPath means a more comprehensive genome to drive our research," said Sean Hofherr, PhD., FACMG, chief of clinical strategy and product development, Broad Clinical Labs. "This technology delivers an impressive ability to interrogate even the most challenging variants in the genome, all in a stunningly simple workflow. And, being able to run it on the NovaSeq X Plus is attractive."More than 30 early access customers have been piloting the technology over the past 16 months, including GeneDx, Rady Children's Hospital, and Baylor College of Medicine. Baylor College of Medicine recently published a pre-print on the technology in medRxiv.The TruPath Genome launch was unveiled today during the Gold Sponsor Workshop at the Advances in Genome Biology and Technology (AGBT) annual meeting in Orlando. Register here for the replay.TruPath Genome was previously referred to as "constellation mapped read technology." Learn more about TruPath Genome here.Use of forward-looking statements
This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) challenges inherent in developing and launching new products and services, including modifying and scaling manufacturing operations, and reliance on third-party suppliers for critical components; (ii) our ability to manufacture robust instrumentation and consumables and develop reliable software solutions; and (iii) the acceptance and adoption by customers of our newly launched or updated products, which may or may not meet our and their expectations, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current quarter.About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.Contacts
Investors:
Illumina Investor Relations
858-291-6421
IR@illumina.com Media:
Christine Douglass
PR@illumina.com










View original content to download multimedia:https://www.prnewswire.com/news-releases/illumina-launches-trupath-genome-setting-a-new-standard-in-genomic-insight-302695923.htmlSOURCE Illumina, Inc.

Original: Illumina launches TruPath Genome, setting a new standard in genomic insight

Illumina unveils roadmap of groundbreaking NovaSeq X advancements in data quality, output, speed, and flexibilityFebruary 23, 2026 9:15 AM
PR Newswire (US)

40% increase in output to 35 billion reads, up to Q70 quality scores, improved turnaround time, and staggered starts are among the updates to be rolled out on all NovaSeq X systems, advancing precision medicine and delivering compounded value for NovaSeq X customers SAN DIEGO, Feb. 23, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today unveiled an 18-month roadmap of innovations that enhance the power and value of the NovaSeq X system. Updates include technology that will deliver up to a Q70 quality score for the first time, along with 30% increased speed and output up to 35 billion reads (35B). Staggered starts and new flow cells go live across the customer base in the coming weeks.Together, these advances increase daily sequencing productivity and expand the range of applications that can be run at scale on a single instrument. With higher output, increased accuracy, faster run times, and new flexible workflow modes, the roadmap delivers compounded value for customers seeking better, faster, and more cost-effective sequencing for their most demanding applications. Improved accuracy ushers in a new era for applications that require ultrasensitivity. Upon rollout, these updates will enhance the performance and value of the 8901 NovaSeq X systems installed globally—the world's largest high-throughput sequencing fleet."The NovaSeq X is already the gold-standard in sequencing, and Illumina is constantly innovating to meet the growing needs of our customers' ambitious projects," said Steve Barnard, PhD, chief technology officer of Illumina. "With our roadmap of advances in quality, speed, output, and flexibility, we are bringing the industry the latest in cutting-edge technology and chemistry. These updates will set the stage for a new wave of research breakthroughs, inspiring a new standard of care in oncology and rare disease, ultimately improving human health."These advances—together with a growing portfolio of multiomic and oncology-focused assays—accelerate Illumina's ability to deliver higher-quality data at a lower total cost. The updates also set the company on track to scale access to whole-genome sequencing research in oncology, including highly sensitive molecular residual disease (MRD) testing, and genetic disease. Roadmap highlightsKey product enhancements expected to be to be rolled out over the next 18 months include:Data quality: Illumina will introduce Q70 quality score technology, enabling cutting-edge oncology applications with unmatched accuracy.Output: NovaSeq X output will increase from 25B to 35B (a 40% uptick) and 10B will increase to 14B, enabling larger and more complex studies on the same instrument.Speed: Illumina will deliver faster turnaround times, with 14B output in 20–22 hours, representing a 30% average improvement in speed on WGS workflows.Flexibility: Illumina will provide enhanced batching flexibility and new high-throughput modes, optimizing flow cell usage to improve read volume for single-cell, proteomics, and Perturb-seq applications.In the coming weeks, Illumina will introduce new flow cells, staggered starts, and software enhancements that expand the sequencer's applications.Flow cells: 5B kits present a mid-size batching option ideally suited for proteomic studies. A 1.5B 600 cycle kit offers longer read length for metagenomics, immune repertoire studies, and amplicon sequencing.Staggered starts: Near-independent flow cell sides allow for asynchronous runs as samples become available, maximizing instrument flexibility and boosting throughput.DRAGEN software advances: DRAGEN pipelines for multiomics, oncology, and genetics.Texas A&M Agri Life utilizes the NovaSeq X to handle large volumes of samples and recently participated in an early access trial of the 1.5B 600 cycle kit and upcoming NovaSeq X software enhancements."The NovaSeq X is becoming better, cheaper, and faster," said Charlie Johnson, PhD, director of Genomics and Bioinformatics. "Since we purchased the NovaSeq X, the data yield for a run has increased by 30% on average, thanks to the advances Illumina continues to introduce. Today, the 600-cycle flow cell delivers everything we hoped for in high-throughput, longer-read sequencing for our metagenomics work."The updates will be rolled out across all NovaSeq X systems, benefiting both current users and future adopters.Illumina NovaSeq X systems are used around the world supporting research and clinical labs that are working to advance science and improve human health. Treatment breakthroughs, diagnostic models, and entire industries have been built on Illumina's next-generation sequencing capabilities, from discoveries in targeted cancer therapy to cancer and rare disease diagnosis, non-invasive prenatal screening, and MRD testing.To learn more about the NovaSeq X, visit https://www.illumina.com/systems/sequencing-platforms/novaseq-x-plus.html.Use of forward-looking statements
This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) our ability to successfully implement NovaSeq X updates on a cost-effective and timely basis, (ii) challenges inherent in developing and launching new products and services, including modifying and scaling manufacturing operations, and reliance on third-party suppliers for critical components; (iii) our ability to manufacture robust instrumentation and consumables and develop reliable software solutions; and (iv) the acceptance and adoption by customers of our newly launched or updated products, which may or may not meet our and their expectations, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current quarter.About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.Contacts
Investors:
Illumina Investor Relations
858-291-6421
IR@illumina.com Media:
Christine Douglass
PR@illumina.comAs of the Q4 financial disclosures, the NovaSeq X active install base was 890 at the end of FY2025.





View original content to download multimedia:https://www.prnewswire.com/news-releases/illumina-unveils-roadmap-of-groundbreaking-novaseq-x-advancements-in-data-quality-output-speed-and-flexibility-302694271.htmlSOURCE Illumina, Inc.

Original: Illumina unveils roadmap of groundbreaking NovaSeq X advancements in data quality, output, speed, and flexibility

Illumina To Webcast Upcoming Investor ConferenceFebruary 17, 2026 3:10 PM
PR Newswire (US)

SAN DIEGO, Feb. 17, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that members of its management team will participate at the following investor conference:Upcoming Investor ConferenceTD Cowen 46th Annual Health Care Conference 2026 on March 3, 2026The fireside chat is scheduled for 12:10pm PT (3:10pm ET).The webcast can be accessed through the Events & Presentations section of Illumina's website at investor.illumina.com. A replay will be archived on Illumina's website for at least 30 days following the event.About IlluminaIllumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and connect with us on X (Twitter), Facebook, LinkedIn, Instagram, TikTok, and YouTube.Investors:
Conor McNamara
+1.858.291.6421
ir@illumina.com Media:
Christine Douglass
pr@illumina.com 



View original content:https://www.prnewswire.com/news-releases/illumina-to-webcast-upcoming-investor-conference-302689766.htmlSOURCE Illumina, Inc.

Original: Illumina To Webcast Upcoming Investor Conference

Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2025February 5, 2026 4:06 PM
PR Newswire (US)

Fourth quarter 2025 results:Revenue of $1.16 billion, up 5% from Q4 2024 (up 4% on a constant currency basis)Ex-China revenue of $1.10 billion, up 8% from Q4 2024 (up 7% on a constant currency basis)GAAP operating margin of 17.4% and non-GAAP operating margin of 23.7%GAAP diluted EPS of $2.16 and non-GAAP diluted EPS of $1.35Fiscal year 2025 results:Revenue of $4.34 billion, flat compared to 2024 on both a reported and constant currency basisEx-China revenue of $4.10 billion, up 2% from 2024 on both a reported and constant currency basisGAAP operating margin of 18.6% and non-GAAP operating margin of 23.1%GAAP diluted EPS of $5.45 and non-GAAP diluted EPS of $4.84Fiscal year 2026 guidance:For fiscal year 2026, we expect:Total company revenue of $4.5 billion to $4.6 billion, representing growth of 4% - 6% on a reported basis, including a 1.5% - 2.0% benefit from the recently closed SomaLogic acquisitionEx-China Organic revenue growth of 2% - 4%, which excludes currency and acquisition impactsNon-GAAP operating margin in the range of 23.3% - 23.5%, including a negative impact of 100bps from the SomaLogic acquisitionNon-GAAP diluted EPS in the range of $5.05 - $5.20, including $0.18 in dilution from the SomaLogic acquisitionSAN DIEGO, Feb. 5, 2026 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced its financial results for the fourth quarter and fiscal year 2025."The Illumina team delivered a strong finish to 2025, marking a return to growth through disciplined execution against our strategy," said Jacob Thaysen, Chief Executive Officer of Illumina. "Momentum built in the second half of the year – especially in clinical markets, where adoption of NGS-based testing is expanding – reinforces our confidence as we enter 2026."Fourth quarter results
GAAP
Non-GAAP (a)Dollars in millions, except per share amountsQ4 2025
Q4 2024
Q4 2025
Q4 2024Revenue$  1,159
$  1,104
$  1,159
$  1,104Gross margin65.5 %
65.9 %
67.0 %
67.4 %Research and development (R&D) expense$     239
$     256
$     238
$     255Selling, general and administrative (SG&A) expense$     310
$     279
$     264
$     271Legal contingency and settlement$         8
$       18
$       —
$       —Operating profit$     202
$     175
$     275
$     218Operating margin17.4 %
15.8 %
23.7 %
19.7 %Tax provision$       44
$       70
$       50
$       47Tax rate11.6 %
37.9 %
19.5 %
23.7 %Net income$     334
$     117
$     208
$     152Diluted EPS$    2.16
$    0.73
$    1.35
$    0.95

(a)See tables in "Results of Operations - Non-GAAP" section below for GAAP and non-GAAP reconciliations.Capital expenditures for free cash flow purposes were $54 million for Q4 2025. Cash flow provided by operations was $321 million, compared to $364 million in the prior year period. Free cash flow (cash flow provided by operations less capital expenditures) was $267 million for the quarter, compared to $322 million in the prior year period. Depreciation and amortization expense was $67 million for Q4 2025. At the close of the quarter, the company held $1.63 billion in cash, cash equivalents and short-term investments.Fiscal year results
GAAP
Non-GAAP (a)Dollars in millions, except per share amounts2025
2024
2025
2024Revenue (b)$  4,343
$  4,332
$  4,343
$  4,332Gross margin66.1 %
67.1 %
68.2 %
68.6 %R&D expense$    967
$    988
$    950
$    982SG&A expense$  1,086
$    900
$  1,009
$  1,069Goodwill and intangible impairment$       —
$        3
$       —
$       —Legal contingency and settlement$      10
$   (456)
$       —
$       —Operating profit$    807
$  1,473
$  1,004
$    922Operating margin18.6 %
34.0 %
23.1 %
21.3 %Tax provision$    236
$    229
$    194
$    204Tax rate21.7 %
20.4 %
20.5 %
23.6 %Net income$    850
$    894
$    756
$    663Diluted EPS$   5.45
$   5.61
$   4.84
$   4.16

(a)See tables in "Results of Operations - Non-GAAP" section below for GAAP and non-GAAP reconciliations.(b)Core Illumina revenue for 2024 included intercompany revenue of $15 million, which, prior to the spin-off of GRAIL in Q2 2024, was eliminated in consolidation.Capital expenditures for free cash flow purposes were $148 million for fiscal year 2025. Cash flow provided by operations was $1.1 billion and free cash flow was $931 million. Depreciation and amortization was $270 million.Key announcements since our last earnings releaseCompleted the acquisition of SomaLogic, expanding Illumina's multiomics portfolio and strengthening its position in scalable, NGS-enabled proteomicsIntroduced the Billion Cell Atlas, the first data product of the BioInsight business, to support AI-enabled drug discovery; AstraZeneca, Merck, and Eli Lilly are the first pharmaceutical partnersAnnounced appointment of veteran genomics leader Eric Green, MD, PhD, as Chief Medical Officer to advance clinical genomics and expand access to precision medicineAchieved progress in China, where the Chinese Ministry of Commerce (MOFCOM) lifted the export ban on Illumina sequencers; the company remains on the Unreliable Entities List (UEL) in China, requiring approvals for instrument purchasesA full list of recent announcements can be found in the company's News Center.Financial outlook and guidance
The company provides forward-looking guidance on a non-GAAP basis, including on a constant currency basis for revenue and revenue growth rates. The company is unable to provide a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP reported financial measures because it is unable to predict with reasonable certainty the impact of items such as acquisition-related expenses, fair value adjustments to contingent consideration, gains and losses from strategic investments, potential future asset impairments, restructuring activities, the ultimate outcome of pending litigation, and currency exchange rate fluctuations without unreasonable effort. These items are uncertain, inherently difficult to predict, depend on various factors, and could have a material impact on GAAP reported results for the guidance period. For the same reasons, the company is unable to address the significance of the unavailable information, which could be material to future results.Conference call information
The conference call will begin at 1:30 pm Pacific Time (4:30 pm Eastern Time) on Thursday, February 5, 2026. Interested parties may access the live webcast via the Investor Info section of Illumina's website or directly through the following link - https://illumina-earnings-call-q4-2025.open-exchange.net/. To ensure timely connection, please join at least ten minutes before the scheduled start of the call. A replay of the conference call will be posted on Illumina's website after the event and will be available for at least 30 days following.Statement regarding use of non-GAAP financial measures
The company reports non-GAAP results for diluted earnings per share, net income, gross margin, operating expenses, including research and development expense, selling general and administrative expense, legal contingency and settlement, and goodwill and intangible impairment, operating income, operating margin, gross profit, other income (expense), tax provision, constant currency revenue and growth, and free cash flow (on a consolidated and, as applicable, segment basis) in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The company's financial measures under GAAP include substantial charges such as amortization of acquired intangible assets among others that are listed in the reconciliations of GAAP and non-GAAP financial measures included in this press release, as well as the effects of currency translation. Management has excluded the effects of these items in non-GAAP measures to assist investors in analyzing and assessing past and future operating performance. Non-GAAP net income, diluted earnings per share and operating margin are key components of the financial metrics utilized by the company's board of directors to measure, in part, management's performance and determine significant elements of management's compensation.The company encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Reconciliations between GAAP and non-GAAP results are presented in the tables of this release.Use of forward-looking statements
This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) changes in the rate of growth in the markets we serve, including the proteomics market; (ii) the volume, timing and mix of customer orders among our products and services; (iii) our ability to adjust our operating expenses to align with our revenue expectations; (iv) our ability to successfully integrate SomaLogic, Inc. and certain other assets we acquired from Standard BioTools Inc. (the SomaLogic Business) into our existing operations and the SomaLogic Business' technology and products into our portfolio; (v) our ability to successfully manage partner and customer relationships in the proteomics market; (vii uncertainty regarding the impact of our inclusion on the "unreliable entities list" by regulatory authorities in China; (vii) uncertainty regarding tariffs imposed or threatened by the U.S. government and its trading partners, and other possible tariffs or trade protection measures and our efforts to mitigate the impact of such tariffs; (viii) our ability to manufacture robust instrumentation and consumables, including the SomaLogic Business' products; (ix) the success of products and services competitive with our own; (x) challenges inherent in developing, manufacturing, and launching new products and services, including expanding or modifying manufacturing operations and reliance on third-party suppliers for critical components; (xi) the impact of recently launched or pre-announced products and services on existing products and services; (xii) our ability to modify our business strategies to accomplish our desired operational goals; (xiii) our ability to realize the anticipated benefits from prior or future actions to streamline and improve our R&D processes, reduce our operating expenses and maximize our revenue growth; (xiv) our ability to further develop and commercialize our instruments, consumables, and products; (xv) to deploy new products, services, and applications, and to expand the markets for our technology platforms; (xvi) the risk of additional litigation arising against us in connection with the GRAIL acquisition; (xvii) our ability to obtain approval by third-party payors to reimburse patients for our products; (xiii) our ability to obtain regulatory clearance for our products from government agencies; (xix) our ability to successfully partner with other companies and organizations to develop new products, expand markets, and grow our business; (xx) uncertainty, or adverse economic and business conditions, including as a result of slowing or uncertain economic growth or armed conflict; (xxi) the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments; and (xxii) legislative, regulatory and economic developments, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current quarter.About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.Illumina, Inc.Condensed Consolidated Balance Sheets(In millions)

December 28,
2025
December 29,
2024ASSETS(unaudited)

Current assets:


Cash and cash equivalents$         1,418
$         1,127Short-term investments215
93Accounts receivable, net854
735Inventory, net564
547Prepaid expenses and other current assets238
244Total current assets3,289
2,746Property and equipment, net759
815Operating lease right-of-use assets370
419Goodwill1,113
1,113Intangible assets, net210
295Deferred tax assets, net454
567Other assets449
348Total assets$         6,644
$         6,303



LIABILITIES AND STOCKHOLDERS' EQUITY


Current liabilities:


Accounts payable$            240
$            221Accrued liabilities846
827Term debt, current portion499
499Total current liabilities1,585
1,547Operating lease liabilities486
554Term debt1,490
1,490Other long-term liabilities360
339Stockholders' equity2,723
2,373Total liabilities and stockholders' equity$         6,644
$         6,303 Illumina, Inc.Condensed Consolidated Statements of Operations(In millions, except per share amounts)(unaudited)

Three Months Ended
Year Ended
December 28,
2025
December 29,
2024
December 28,
2025
December 29,
2024Revenue:






Product revenue$            990
$            939
$        3,709
$        3,656Service and other revenue169
165
634
716Total revenue1,159
1,104
4,343
4,372Cost of revenue:






Cost of product revenue (a)312
278
1,107
1,017Cost of service and other revenue (a)72
82
300
367Amortization of acquired intangible assets16
16
66
127Total cost of revenue400
376
1,473
1,511Gross profit759
728
2,870
2,861Operating expense:






Research and development (a)239
256
967
1,169Selling, general and administrative (a)310
279
1,086
1,092Goodwill and intangible impairment—
—
—
1,889Legal contingency and settlement8
18
10
(456)Total operating expense557
553
2,063
3,694Income (loss) from operations202
175
807
(833)Other income (expense), net176
13
279
(346)Income (loss) before income taxes378
188
1,086
(1,179)Provision for income taxes44
1
236
44Net income (loss)$            334
$            187
$           850
$      (1,223)Earnings (loss) per share:






Basic$           2.18
$           1.17
$          5.47
$        (7.69)Diluted$           2.16
$           1.17
$          5.45
$        (7.69)Shares used in computing earnings (loss) per share:






Basic153
159
155
159Diluted154
160
156
159
The consolidated results for YTD 2024 include the results for GRAIL which was spun off on June 24, 2024. (a) Includes stock-based compensation expense for stock-based awards: 
Three Months Ended
Year Ended
December 28,
2025
December 29,
2024
December 28,
2025
December 29,
2024Cost of product revenue$                4
$                6
$            20
$            25Cost of service and other revenue1
1
3
6Research and development23
31
107
146Selling, general and administrative35
42
145
194Stock-based compensation expense before taxes$              63
$              80
$           275
$           371 Illumina, Inc.Condensed Statements of Cash Flows(In millions)(unaudited)
TABLE 1: CONSOLIDATED STATEMENTS OF CASH FLOWS AND FREE CASH FLOWS:

Three Months Ended
Year Ended
December 28,
2025
December 29,
2024
December 28,
2025
December 29,
2024Net cash provided by operating activities$            321
$           364
$        1,079
$           837Net cash provided by (used in) investing activities108
(48)
(55)
(178)Net cash used in financing activities(63)
(47)
(744)
(570)Effect of exchange rate changes on cash and cash equivalents2
(11)
11
(10)Net increase in cash and cash equivalents368
258
291
79Cash and cash equivalents, beginning of period1,050
869
1,127
1,048Cash and cash equivalents, end of period$         1,418
$        1,127
$        1,418
$        1,127







Calculation of free cash flow:






Net cash provided by operating activities$            321
$           364
$        1,079
$           837Purchases of property and equipment(54)
(42)
(148)
(142)Free cash flow (a)$            267
$           322
$           931
$           695
The consolidated results for YTD 2024 include the results for GRAIL which was spun off on June 24, 2024. TABLE 2: CORE ILLUMINA FREE CASH FLOWS:

Three Months Ended
Year Ended
December 28,
2025
December 29,
2024
December 28,
2025
December 29,
2024Net cash provided by operating activities$           321
$           364
$        1,079
$        1,207Purchases of property and equipment(54)
(42)
(148)
(137)Free cash flow (a)$           267
$           322
$           931
$        1,070

(a)Free cash flow, which is a non-GAAP financial measure, is calculated as net cash provided by operating activities reduced by purchases of property and equipment. Free cash flow is useful to management as it is one of the metrics used to evaluate our performance and to compare us with other companies in our industry. However, our calculation of free cash flow may not be comparable to similar measures used by other companies. Illumina, Inc.Results of Operations - Constant Currency Revenue(Dollars in millions)(unaudited)
 TABLE 1: CORE ILLUMINA - CONSTANT CURRENCY REVENUE:

Three Months Ended
Year Ended
December 28,
2025
December 29,
2024
% Change
December 28,
2025
December 29,
2024
% ChangeRevenue$           1,159
$           1,104
5 %
$        4,343
$        4,332
— %Less: Hedge effect(4)
5


(5)
15

Revenue, excluding hedge effect1,163
1,099


4,348
4,317

Less: Exchange rate effect16
—


21
—

Constant currency revenue (a)$           1,147
$           1,099
4 %
$        4,327
$        4,317
— % TABLE 2: CONSOLIDATED - CONSTANT CURRENCY REVENUE:

Year Ended
December 28,
2025
December 29,
2024
% ChangeRevenue$            4,343
$            4,372
(1) %Less: Hedge effect(5)
15

Revenue, excluding hedge effect4,348
4,357

Less: Exchange rate effect21
—

Constant currency revenue (a)$            4,327
$            4,357
(1) % The consolidated results for YTD 2024 include the results for GRAIL which was spun off on June 24, 2024.
TABLE 3: CORE ILLUMINA - EXCLUDING GREATER CHINA - CONSTANT CURRENCY REVENUE:

Three Months Ended
Year Ended
December 28,
2025
December 29,
2024
% Change
December 28,
2025
December 29,
2024
% ChangeRevenue$       1,104
$       1,024
8 %
$       4,100
$      4,024
2 %Less: Hedge effect(4)
3


(8)
10

Revenue, excluding hedge effect1,108
1,021


4,108
4,014

Less: Exchange rate effect16
—


22
—

Constant currency revenue (a)$       1,092
$       1,021
7 %
$       4,086
$       4,014
2 %

(a)Constant currency revenue growth, which is a non-GAAP financial measure, is calculated using comparative prior period foreign exchange rates to translate current period revenue, net of the effects of hedges. Illumina, Inc.Results of Operations - Non-GAAP(In millions, except per share amounts)(unaudited) 
TABLE 1: RECONCILIATION OF GAAP AND NON-GAAP DILUTED EARNINGS (LOSS) PER SHARE: 

Three Months Ended
Year Ended
December 28,
2025
December 29,
2024
December 28,
2025
December 29,
2024
Core/
Consolidated
Core
Illumina
Consolidated
Core/
Consolidated
Core
Illumina
ConsolidatedGAAP diluted earnings (loss) per share$          2.16
$    0.73
$         1.17
$          5.45
$    5.61
$        (7.69)Cost of revenue (b)0.12
0.10
0.10
0.60
0.40
0.81R&D expense (b)0.01
0.01
0.01
0.11
0.04
0.04SG&A expense (b)0.30
0.04
0.04
0.48
(1.06)
(0.97)Goodwill and intangible impairment (b)—
—
—
—
0.02
11.88Legal contingency and settlement (b)0.05
0.11
0.11
0.06
(2.87)
(2.87)Other (income) expense, net (b)(1.25)
(0.19)
(0.19)
(2.13)
1.86
1.85Provision for income taxes (b)(0.04)
0.15
(0.38)
0.27
0.16
(0.60)Non-GAAP diluted earnings per share (a)$          1.35
$    0.95
$         0.86
$          4.84
$    4.16
$         2.45 TABLE 2: RECONCILIATION OF GAAP AND NON-GAAP NET INCOME (LOSS):

Three Months Ended
Year Ended
December 28,
2025
December 29,
2024
December 28,
2025
December 29,
2024
Core/
Consolidated
Core
Illumina
Consolidated
Core/
Consolidated
Core
Illumina
ConsolidatedGAAP net income (loss)$           334
$        117
$           187
$           850
$       894
$      (1,223)Cost of revenue (b)18
17
17
94
64
129R&D expense (b)1
1
1
17
6
6SG&A expense (b)45
7
7
76
(168)
(155)Goodwill and intangible impairment (b)—
—
—
—
3
1,889Legal contingency and settlement (b)8
18
18
10
(456)
(456)Other (income) expense, net (b)(192)
(31)
(31)
(333)
295
295Provision for income taxes (b)(6)
23
(61)
42
25
(95)Non-GAAP net income (a)$           208
$        152
$           138
$           756
$       663
$           390

Amounts in tables are rounded to the nearest millions. As a result, certain amounts may not recalculate.

The consolidated results for Q4 2024 and YTD 2024 include the results for GRAIL which was spun off on June 24, 2024.

(a)Non-GAAP net income and diluted earnings per share exclude the effects of the pro forma adjustments detailed above. Non-GAAP net income and diluted earnings per share are key components of the financial metrics utilized by the company's board of directors to measure, in part, management's performance and determine significant elements of management's compensation. Management has excluded the effects of these items in these measures to assist investors in analyzing and assessing our past and future operating performance.(b)Refer to Reconciliations between GAAP and Non-GAAP Results of Operations for details of amounts. Illumina, Inc.Results of Operations - Non-GAAP (continued)(Dollars in millions)(unaudited) TABLE 3: RECONCILIATION OF GAAP AND NON-GAAP RESULTS OF OPERATIONS AS A PERCENT OF REVENUE:


Three Months Ended
December 28, 2025
December 29, 2024GAAP gross profit (b)$             75965.5 %
$             72865.9 %Acquisition-related costs (c)161.3 %
171.5 %Transformational initiatives (d)20.2 %
——Non-GAAP gross profit (a)$             77767.0 %
$             74567.4 %





GAAP R&D expense$             23920.6 %
$             25623.2 %Acquisition-related costs (c)——
(1)(0.1) %Transformational initiatives (d)(1)(0.1) %
——Non-GAAP R&D expense$             23820.5 %
$             25523.1 %





GAAP SG&A expense$             31026.7 %
$             27925.2 %Acquisition-related costs (c)(21)(1.8) %
70.7 %Transformational initiatives (d)(6)(0.5) %
(15)(1.3) %Other (g)(19)(1.6) %
——Non-GAAP SG&A expense$             26422.8 %
$             27124.6 %





GAAP legal contingency and settlement$                 80.7 %
$               181.7 %Legal contingency and settlement (h)(8)(0.7) %
(18)(1.7) %Non-GAAP legal contingency and settlement$                ——
$                ——





GAAP operating profit$             20217.4 %
$             17515.8 %Cost of revenue181.6 %
171.5 %R&D costs10.1 %
10.1 %SG&A costs463.9 %
70.6 %Legal contingency and settlement80.7 %
181.7 %Non-GAAP operating profit (a)$             27523.7 %
$             21819.7 %





GAAP other income, net$             17615.2 %
$               131.2 %Strategic investment gain, net (e)(192)(16.6) %
(31)(2.9) %Non-GAAP other expense, net (a)$              (16)(1.4) %
$              (18)(1.7) %
Amounts in tables are rounded to the nearest millions. As a result, certain amounts may not recalculate.  Illumina, Inc.Results of Operations - Non-GAAP (continued)(Dollars in millions)(unaudited)
TABLE 3: RECONCILIATION OF GAAP AND NON-GAAP RESULTS OF OPERATIONS AS A PERCENT OF REVENUE:

Year Ended
December 28, 2025
December 29, 2024
Core/Consolidated
Core Illumina
GRAIL
Elims
ConsolidatedGAAP gross profit (loss) (b)$     2,87066.1 %
$ 2,90967.1 %
$       (38)
$  (10)
$   2,86165.4 %Acquisition-related costs (c)661.5 %
631.5 %
65
—
1283.0 %Transformational initiatives (d)50.1 %
1—
—
—
1—Intangible impairment (f)230.5 %
——
—
—
——Non-GAAP gross profit (a)$     2,96468.2 %
$ 2,97368.6 %
$         27
$  (10)
$   2,99068.4 %












GAAP R&D expense$        96722.3 %
$    98822.8 %
$       189
$     (8)
$   1,16926.7 %Acquisition-related costs (c)(1)—
(4)(0.1) %
—
—
(4)(0.1) %Transformational initiatives (d)(16)(0.4) %
(2)—
—
—
(2)—Non-GAAP R&D expense$        95021.9 %
$    98222.7 %
$       189
$     (8)
$   1,16326.6 %












GAAP SG&A expense$     1,08625.0 %
$    90020.7 %
$       192
$     —
$   1,09225.0 %Acquisition-related costs (c)(16)(0.4) %
2275.2 %
(13)
—
2144.8 %Transformational initiatives (d)(39)(0.9) %
(58)(1.3) %
(1)
—
(59)(1.3) %Other (g)(22)(0.5) %
——
—
—
——Non-GAAP SG&A expense$     1,00923.2 %
$ 1,06924.6 %
$       178
$     —
$   1,24728.5 %












GAAP goodwill and intangible impairment$           ——
$         30.1 %
$   1,886
$     —
$   1,88943.2 %Goodwill impairment (f)——
——
(1,466)
—
(1,466)(33.5) %Intangible (IPR&D) impairment (f)——
(3)(0.1) %
(420)
—
(423)(9.7) %Non-GAAP goodwill and intangible impairment$           ——
$       ——
$         —
$     —
$         ——












GAAP legal contingency and settlement$          100.2 %
$  (456)(10.5) %
$         —
$     —
$    (456)(10.4) %Legal contingency and settlement (h)(10)(0.2) %
45610.5 %
—
—
45610.4 %Non-GAAP legal contingency and settlement$           ——
$       ——
$         —
$     —
$         ——












GAAP operating profit (loss)$        80718.6 %
$ 1,47334.0 %
$ (2,305)
$     (1)
$    (833)(19.1) %Cost of revenue942.2 %
641.5 %
65
—
1293.0 %R&D costs170.4 %
60.1 %
—
—
60.1 %SG&A costs761.7 %
(168)(3.9) %
13
—
(155)(3.5) %Goodwill and intangible impairment——
30.1 %
1,886
—
1,88943.2 %Legal contingency and settlement100.2 %
(456)(10.5) %
—
—
(456)(10.4) %Non-GAAP operating profit (loss) (a)$     1,00423.1 %
$    92221.3 %
$     (341)
$     (1)
$      58013.3 %












GAAP other income (expense), net$        2796.4 %
$  (350)(8.1) %
$           5
$     (1)
$    (346)(7.9) %Strategic investment (gain) loss, net (e)(333)(7.6) %
3087.1 %
—
—
3087.1 %Other (i)——
(13)(0.3) %
—
—
(13)(0.3) %Non-GAAP other (expense) income, net (a)$         (54)(1.2) %
$     (55)(1.3) %
$           5
$     (1)
$      (51)(1.1) %

Amounts in tables are rounded to the nearest millions. As a result, certain amounts may not recalculate.

Percentages of revenue are calculated based on the revenue of the respective segment.

The consolidated results for YTD 2024 include the results for GRAIL which was spun off on June 24, 2024.
(a)Non-GAAP gross profit, included within non-GAAP operating profit (loss), is a key measure of the effectiveness and efficiency of manufacturing processes, product mix and the average selling prices of our products and services. Non-GAAP operating profit (loss) and non-GAAP other income (expense), net exclude the effects of the pro forma adjustments as detailed above. Non-GAAP operating margin is a key component of the financial metrics utilized by the company's board of directors to measure, in part, management's performance and determine significant elements of management's compensation. Management has excluded the effects of these items in these measures to assist investors in analyzing and assessing past and future operating performance.(b)Reconciling amounts are recorded in cost of revenue.(c)Amounts for Q4 2025 consist of $16 million for amortization of intangible assets (cost of revenue), $11 million for fair value adjustments on our contingent consideration liabilities (SG&A) and $10 million related primarily to legal and other expenses for the SomaLogic acquisition and legal expenses for the GRAIL acquisition (SG&A). Amounts for YTD 2025 consist primarily of $66 million for amortization of intangible assets (cost of revenue) and $33 million related primarily to legal and other expenses for the SomaLogic acquisition, legal expenses for the GRAIL acquisition and a lease impairment (SG&A), offset by $18 million for fair value adjustments on our contingent consideration liabilities (SG&A). Amounts for Q4 2024 consist of $17 million for amortization of intangible assets and $5 million related primarily to legal and other expenses for the acquisition and divestiture of GRAIL, offset by $11 million for fair value adjustments on our contingent consideration liabilities. Consolidated amounts for YTD 2024 consist of $315 million for fair value adjustments on our contingent consideration liabilities, offset by $131 million for amortization of intangible assets and $102 million primarily related to legal and other expenses for the acquisition and divestiture of GRAIL.(d)Amounts for Q4 2025 and YTD 2025 consist primarily of employee severance costs related to restructuring activities ($47 million in YTD 2025) and costs related to implementation efforts to upgrade our ERP system ($14 million in YTD 2025) (SG&A). Amounts for Q4 2024 and YTD 2024 consist primarily of lease and other asset impairments and employee severance costs related to restructuring activities.(e)Amounts consist of realized and unrealized gains (losses) and impairments on our investments.(f)Amounts for YTD 2025 consist of an intangible impairment related to Core Illumina. Amounts for YTD 2024 consist of goodwill and IPR&D impairments related to GRAIL and IPR&D impairment related to Core Illumina.(g)Amounts for Q4 2025 and YTD 2025 consist of a $19 million donation to the Illumina Foundation. Amount for YTD 2025 also consists of $3 million for board membership changes.(h)Amounts for YTD 2024 primarily consist of the reversal of the accrued EC fine, including accrued interest.(i)Consolidated amounts for YTD 2024 consist of $15 million for fair value adjustments on Helix contingent value right, offset by $2 million for unrealized gains/losses related to foreign currency balance sheet remeasurement of EC fine liability and unrealized/realized mark-to-market gains/losses on hedge associated with the EC fine. Illumina, Inc.Results of Operations - Non-GAAP (continued)(Dollars in millions)(unaudited)
TABLE 4: RECONCILIATION OF GAAP AND NON-GAAP TAX PROVISION:

Three Months Ended
December 28, 2025
December 29, 2024
Core/Consolidated
Core Illumina
ConsolidatedGAAP tax provision$        4411.6 %
$     7037.9 %
$       10.6 %Income tax provision (b)(11)

(13)

(13)
GILTI, US foreign tax credits, global minimum top-up tax (c)—

5

51
Non-GAAP tax expense (d)17

(15)

23
Non-GAAP tax provision (a)$        5019.5 %
$     4723.7 %
$     6231.1 %









Year Ended
December 28, 2025
December 29, 2024
Core/Consolidated
Core Illumina
ConsolidatedGAAP tax provision$       23621.7 %
$    22920.4 %
$     44(3.8) %Income tax provision (b)(19)

(16)

(16)
GILTI, US foreign tax credits, global minimum top-up tax (c)—

(82)

(90)
Non-GAAP tax expense (d)(23)

73

201
Non-GAAP tax provision (a)$       19420.5 %
$    20423.6 %
$   13926.3 %

The consolidated results for Q4 2024 and YTD 2024 include the results for GRAIL which was spun off on June 24, 2024.

(a)Non-GAAP tax provision excludes the effects of the pro forma adjustments detailed above, which have been excluded to assist investors in analyzing and assessing past and future operating performance.(b)Amounts represent the difference between book and tax accounting related to stock-based compensation cost.(c)Amounts represent the impact of GRAIL pre-acquisition net operating losses on GILTI, the utilization of US foreign tax credits, and the Pillar Two global minimum top-up tax, which no longer applies for 2025 since the GRAIL pre-acquisition net operating losses were fully utilized in prior years.(d)Non-GAAP tax expense includes a one-time $42 million valuation allowance adjustment recorded in Q3 2025 against deferred tax assets associated with certain U.S. foreign tax credits as a result of the U.S. tax legislation that was signed on July 4, 2025 and the tax impact of the non-GAAP adjustments listed in Table 2. Investors:
Conor McNamara
+1.858.291.6421
ir@illumina.comMedia:
Christine Douglass
pr@illumina.com



View original content:https://www.prnewswire.com/news-releases/illumina-reports-financial-results-for-fourth-quarter-and-fiscal-year-2025-302680728.htmlSOURCE Illumina, Inc.

Original: Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2025

Illumina and the San Diego Zoo Wildlife Alliance partner to sequence the Frozen Zoo®, supporting critical conservation genetics efforts globallyFebruary 3, 2026 9:15 AM
PR Newswire (US)

Illumina will sequence up to 4,000 unique individual animals across 1,300 species, unlock genomic insights from 50-year-old biological samplesSequencing connects decades of preserved biodiversity with the latest multiomic technologiesSAN DIEGO, Feb. 3, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced a sequencing agreement with the San Diego Zoo Wildlife Alliance (SDZWA)'s Frozen Zoo®. The 50-year-old biobank is the world's most comprehensive and diverse collection of living cells from threatened and endangered species across the animal kingdom. Illumina will sequence up to 4,000 samples representing 1,300 species in the Frozen Zoo®. Genomic insights will be applied to real-world conservation challenges and efforts to safeguard animal species worldwide. A subset of samples will be used for groundbreaking multiomic research, geared toward unlocking vital insights into wildlife medicine, evolutionary biology, and biodiversity preservation.







"Illumina is proud to partner with SDZWA to power the next era of the Frozen Zoo," said Cande Rogert, vice president and global head of Advanced Sciences at Illumina. "This collaboration is a wonderful example of the way multiomic technologies can activate the potential of these critical biodiversity biobanks."Conservation scientists across the globe are racing against time to collect samples from threatened and endangered species. Those samples are preserved in biobanks like the Frozen Zoo®, where they serve as a repository of increasingly fragile biodiversity. Sequencing those biobanked samples gives researchers genomic insights that are useful to help protect species and promote ecological resilience."This collaboration marks a new era of genomic discovery that will accelerate our capacity to halt and reverse biodiversity loss," said Megan Owen, SDZWA's Benirschke Endowed Vice President of Conservation Science. "The next fifty years of the Frozen Zoo will rely on a global network of conservation scientists, as well as scalable multiomic technology to maximize the impact of biobanked samples."The San Diego Zoo Wildlife Alliance has partnered with the International Union for Conservation of Nature (IUCN) Species Survival Commission as a Center for Species Survival focused on biodiversity banking. The partnership with Illumina aims to illustrate the value of sequencing in conservation efforts globally. To make the effort possible, Illumina will generate whole-genome sequencing data from samples representing wildlife in the Frozen Zoo®, which will be made available for research to the San Diego Zoo Wildlife Alliance and its collaborators.A selection of the samples will be available for collaborative research projects, where Illumina's multiomic solutions will help conservation researchers unlock information about genetic diversity and population history. The collaboration will also help to validate multiomic workflows for conservation science, ensuring they perform reliably with non-human samples."My father, Dr. Kurt Benirschke, founded the Frozen Zoo way back in 1975, believing it was important to preserve the DNA of rare and endangered species, but not knowing exactly why or how," said Rolf Benirschke, the board chair of the SDZWA Board of Trustees. "If he were alive today, he would be smiling knowing that his vision has led to this important collaboration with Illumina that will dramatically expand and amplify the science of conservation."Genomics insights are driving a deeper understanding of koala cancer risk
Illumina collaborates with the San Diego Zoo Wildlife Alliance through its iConserve program and, in addition to the Frozen Zoo® collaboration, has also worked on lemur conservation in Madagascar and elephant genetic mapping in Africa. iConserve advances conservation by enabling projects with acute conservation needs and advocating for genomics as a conservation tool to support species protection and management decisions.One recent iConserve project, published last month in Nature Communications, demonstrates how sequencing koala genomes can inform conservation management decisions for koalas in zoos and in the wild. Koalas are susceptible to a retrovirus associated with cancers that are difficult for zoo veterinarians to detect and treat. Through the iConserve program, Illumina generated high-coverage whole-genome sequencing data for 91 San Diego Zoo koalas, from samples collected over multiple decades. Those sequences show how these viruses integrate into the koala genome across populations. This collaborative effort led to the identification of inherited and newly arising viral integrations in koala DNA. It also advanced the development of genetic risk scores, and the creation of a longevity breeding index—tools that can help reduce cancer risk and support healthier outcomes for koala populations in zoos and in the wild.About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.About the San Diego Zoo Wildlife Alliance 
San Diego Zoo Wildlife Alliance, a nonprofit conservation leader, inspires passion for nature and collaboration for a healthier world. The Alliance supports innovative conservation science through global partnerships and groundbreaking efforts at the world-famous San Diego Zoo and San Diego Zoo Safari Park, both leading zoological institutions and accredited botanical gardens. Through wildlife care expertise, cutting-edge science and continued collaboration, more than 44 endangered species have been reintroduced to native habitats. The Alliance reaches over 1 billion people annually through its two conservation parks and media channels in 170 countries, including San Diego Zoo Wildlife Explorers television, available in children's hospitals across 14 countries. Wildlife Allies—members, donors and guests—make success possible.About the San Diego Zoo Wildlife Alliance's Frozen Zoo® 
The Frozen Zoo® is the world's first large-scale cryogenic biological bank dedicated to preserving living cells and reproductive material from wildlife—and remains the largest, most diverse collection of its kind. Founded in 1975 by Kurt Benirschke, M.D., the Frozen Zoo today holds over 11,500 samples from 4,000 unique individuals across 1,300 species. Stored in liquid nitrogen at minus 320 degrees Fahrenheit, the collection includes cells, embryos and gametes from mammals, birds, reptiles, amphibians, fish, plants, marine invertebrates and insects. The Frozen Zoo® is one of six unique San Diego Zoo Wildlife Alliance biobanking collections that make up its Wildlife Biodiversity Bank. Together these collections offer a variety of approaches to preserving biodiversity. Learn more at sdzwa.org/frozen-zoo.ContactsIllumina
For media:
Christine Douglass
PR@illumina.comSan Diego Zoo Wildlife Alliance
For media:
Meghan Breen
mbreen@sdzwa.org



View original content to download multimedia:https://www.prnewswire.com/news-releases/illumina-and-the-san-diego-zoo-wildlife-alliance-partner-to-sequence-the-frozen-zoo-supporting-critical-conservation-genetics-efforts-globally-302676948.htmlSOURCE Illumina, Inc.

Original: Illumina and the San Diego Zoo Wildlife Alliance partner to sequence the Frozen Zoo®, supporting critical conservation genetics efforts globally

Illumina completes acquisition of SomaLogicJanuary 30, 2026 9:05 AM
PR Newswire (US)

Deeply expands leadership in proteomics and multiomicsCombined capabilities bring high scalability, flexibility, and affordability into protein analysis Combination leverages SomaScan with Illumina's NGS ecosystem, DRAGEN software, and Illumina Connected Multiomics to rapidly transform insights into discoveries SAN DIEGO, Jan. 30, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that it has completed its acquisition of SomaLogic, a leader in data-driven proteomics technology. The highly complementary proteomics capabilities expand Illumina's multiomics portfolio, strengthening customer access to proteomic insights at scale to help drive faster drug discovery and positively impact health care.







"Welcoming the SomaLogic team to Illumina is an important milestone in executing the multiomics strategy we outlined in 2024," said Jacob Thaysen, chief executive officer of Illumina. "By combining SomaLogic's highly differentiated proteomics technology with Illumina's industry-leading innovation and global reach, we are strengthening our ability to deliver scalable insights across genomics and proteomics, helping customers unlock more from every sample in support of better outcomes for patients."SomaLogic's technologies provide deep insights into protein function, interactions, and modifications, helping to accelerate understanding of complex biology and human health. Customers will benefit from the combined power of SomaScan, Illumina Protein Prep, SomaSignal Tests, DRAGEN software, and Illumina Connected Multiomics to generate rich multiomic datasets at scale, with the flexibility to adopt the tools and workflows that best match their needs.Illumina is building new, scalable growth businesses that complement and accelerate its high-throughput sequencing franchise. The SomaLogic acquisition ideally positions Illumina for growth in the expanding proteomics market by increasing customer access to SomaLogic's technologies and service offerings, coupled with Illumina's product innovation and global market reach.Illumina remains an open, accessible, and enabling next-generation sequencing (NGS) platform, and will work closely with customers to provide continuity of products, services, and support as SomaLogic's portfolio is integrated into Illumina's product and solutions roadmap.Illumina and SomaLogic have partnered in proteomics co-development since late 2021, when the companies entered into an agreement to bring the SomaScan Proteomics Assay onto Illumina's high-throughput NGS platforms. The completed acquisition builds on this foundation, expanding Illumina's presence in the large and growing proteomics market and advancing its leadership in multiomics. The company will continue to support SomaLogic customers and partnerships, including existing service providers using SomaLogic's array-based readout.Illumina acquired SomaLogic and other specified assets from Standard BioTools for $350 million, subject to customary adjustments, in cash paid at closing, plus up to $75 million in near-term performance-based milestones and performance-based royalties. The deal was funded with cash on hand, and Illumina will discuss the financial implications of the transaction in our upcoming earnings call scheduled for February 5, 2026.To learn more, visit https://www.illumina.com/company/news-center/somalogic-acquisition.html.Use of forward-looking statements
This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: (i) the future conduct and growth of the business and the markets in which we operate, including the proteomics market; (ii) the success of products and services competitive with our own; (iii) our ability to successfully integrate the SomaLogic business into our existing operations and the SomaLogic business's technology and products into our portfolio; (iv) our ability to sell the products and further develop the SomaLogic business's technology; (v) our ability to successfully manage partner and customer relationships in the proteomics market; (vi) our ability to manufacture robust instrumentation and consumables including the SomaLogic business's products; (vii) challenges inherent in developing, manufacturing, and launching new products and services, including expanding or modifying manufacturing operations and reliance on third-party suppliers for critical components; and (viii) customer uptake of, and satisfaction with, new products and services, together with other factors detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We undertake no obligation, and do not intend, to update these forward-looking statements, to review or confirm analysts' expectations, or to provide interim reports or updates on the progress of the current quarter. About Illumina
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X, Facebook, LinkedIn, Instagram, TikTok, and YouTube.ContactsInvestors: 
Illumina Investor Relations 
858-291-6421 
IR@illumina.com Media: 
Christine Douglass 
PR@illumina.com



View original content to download multimedia:https://www.prnewswire.com/news-releases/illumina-completes-acquisition-of-somalogic-302674789.htmlSOURCE Illumina, Inc.

Original: Illumina completes acquisition of SomaLogic

ILMN on an upswing

https://www.illumina.com/

Scumbag Scott Gottlieb is on the board of this company. Short it till it's dead. He should be in prison for the rest of his life.
https://www.illumina.com/company/about-us/board-of-directors.html

Yep and I think it’s a big winner for next 5 years.

only owned stock for a few weeks ... but i don't understand why today's announcement is negative ??? anybody understand why stock is reacting poorly to a positive partnership???

Hello !! Anyone home? Anybody following this stock?

$ILMN Illumina (NASDAQ:ILMN) Has a New Complementary Technology Produced by Bionano Genomics (NASDAQ: $BNGO )
https://www.twst.com/news/illumina-nasdaqilmn-new-complementary-technology-produced-bionano-genomics-nasdaqbngo/

Bionano Genomics, Inc. $BNGO Takes On Illumina, Inc. $ILMN ttps://manufacturinmarket.com/2019/10/26/bionano-genomics-inc-bngo-takes-on-illumina-inc-ilmn/

$ILMN over to $BNGO Bionano Genomics, Inc. operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets, and to streamline the study of changes in chromosomes, which is known as cytogenetics. Its Saphyr system comprises an instrument, chip consumables, reagents, and a suite of data analysis tools. The company's Bionano prep kits and labeling kits provide the critical reagents and protocols needed to extract and label high molecular weight DNA for use with the Saphyr system; and data solutions offering includes a suite of hardware and software for end-to-end experiment management, algorithms for assembling genome maps, and algorithms and databases for bioinformatics processing. It sells its products for research use applications primarily to laboratories associated with academic and governmental research institutions, as well as to pharmaceutical, biotechnology, and contract research companies in the United States and Canada, Europe, the Middle East, India, Africa, China, Japan, South Korea, Singapore, and Australia. The company was formerly known as BioNano Genomics, Inc. and changed its name to Bionano Genomics, Inc. in July 2018. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.

Watching for entry

ILMN SPX


http://schrts.co/HapvWzvt

Float 128.41 M

PE Ratio 51.90

Earnings Per Share (EPS)=5.63

ART HILL MAR 14, 2019

N.p.

Thanks Jindal:
Sure hope they can make it work acceptably!

https://www.theguardian.com/science/2019/feb/24/the-10-minute-test-for-cancer-pioneering-methods-blood-test-detection-tumours-lung-breast-colorectal

https://www.medgadget.com/2017/10/tissue-microarray-industry-2017-global-market-growth-trends-share-and-demands-research-report.html

Analysis of Tissue Microarray Industry Key Manufacturers:

Agilent Technologies
Illumina
Protein Biotechnologies Inc
Asterand Bioscience
Pantomics Inc
Applied Microarrays
Arrayit
Phalanx Biotech
Qiagen
Takara Bio.

Thanks PT: They want you to sign up to read it though..oh well.

I just read a newsletter report on a researcher's paper that said he'd sequenced samples on ILMN's newest high throughput sequencer and then on the prior generation's sequencer and the results didn't agree.
The report said ILMN said the discrepancy was inconsequential...but...

That's very interesting!
Thanks PT.

Illumina Acquires BlueGnome

https://www.genomeweb.com/arrays/illumina-acquires-bluegnome

This link might work...

Connect the dots

It would have if the link worked for me...but a step in the right direction.

BLACKROCK INSTITUTIONAL TRUST COMPANY, N.A.

12/31/2016 3,856,897 (20,258) (0.52) 665,932

http://www.nasdaq.com/symbol/ilmn/institutional-holdings

Does this work for you??

K

The totally inappropriate biblical quotation on the premier genetic sequencing companies' stock board....is "What gives me that impression".

Well almost recovered since October...

You are an opportunistic quasi-religious loonie

What gives you that impression??

This message has nothing to do with ILMN!
You are an opportunistic quasi-religious loonie
who impolitely imposes his antiquated values on innocent victims.
That's extremely offensive!
Don't do that again please...you demean the bible..

You shall not covet your neighbor’s house. You shall not covet your neighbor’s wife, or his male or female servant, his ox or donkey, or anything that belongs to your neighbor.

—?Exodus 20:17

ILMN

Just released a new series of sequencers "NovaSeq" with great advantages.
SP up to where i bought in, finally.
Many new deals and collaborations.
In many ways, this company is the genomics kingpin.
I feel kinda dumb for not buying in years ago when i first did some DD on it.
In the long run, it should be a great investment.
Wonder why this board is so dead.